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Poxviruses subvert the host immune response by producing immunomodulatory virulence 
factors, including a complement regulatory protein.  Ectromelia virus provides a mouse 
model for human smallpox infection where the virus and the host’s immune response have 
also co-evolved.  Using this model, we investigated the role of the complement system in a 
poxvirus infection.  Ectromelia virus inoculated via multiple routes caused increased 
mortality by 7 to 10 days post-infection in C57BL/6 mice that lack C3, the central 
component of the complement cascade.  In C3-/- mice, ectromelia virus disseminated earlier 
to target organs and generated higher peak titers compared to the congenic controls.  
Specifically, increased hepatic inflammation and necrosis correlated with these higher tissue 
titers and likely contributed to the morbidity in the C3-/- mice.  In vitro, the complement 
system in naïve C57BL/6 mouse sera neutralized ectromelia virus, primarily through the 
recognition of the virion by natural antibody and activation of the classical and alternative 
pathways.  Sera deficient in classical or alternative pathway components or antibody had 
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reduced ability to neutralize viral particles, which likely contributed to increased viral 
dissemination and disease severity in vivo.  The increased mortality of C4-/- or Factor B-/- mice 
also indicates that these two pathways of complement activation are required for survival.  
The importance of complement in the immune response to poxviruses accounts for why the 
virus encodes a potent complement regulatory protein, EctroMelia Inhibitor of Complement 
Enzymes (EMICE).  Infected cells produce EMICE within 6-8 hours of infection.  
Recombinant EMICE produced in E. coli has cofactor activity against C3 and C4, regulates 
mouse complement, and protects ectromelia virus in vitro.  In summary, the complement 
system acts in the first few minutes, hours, and days to control this poxviral infection, and 
the virus counters this activity though production of its regulatory protein EMICE. 
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Chapter 1 
Introduction  
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Clinical Significance  
Poxviruses remain a threat to the human population despite the eradication decades ago of 
naturally circulating variola virus (VARV), the causative agent of smallpox.  Smallpox, with its 
up to 30% mortality rate, could devastate the large unvaccinated population if released 
accidentally or by bioterrorists [1].  Closely related monkeypox virus (MPXV) has also 
emerged as a human pathogen, and certain strains of MPXV cause a disease that is clinically 
indistinguishable from smallpox [2].  A less virulent strain of MPXV has already caused one 
outbreak in the United States [3].  The current smallpox vaccine can cause life threatening 
complications [4].  Antiviral options are limited and ineffective at treating smallpox or 
vaccine related disease.  A better understanding of poxviral pathogenesis is required to devise 
novel therapeutic options for smallpox and other emerging poxviral infections.  
Furthermore, the study of this family of infectious agents has provided insights into viral 
pathogenesis and revealed novel facets of the host’s immune response. 
Poxviruses’ Infection and Replication 
Within the poxviridae family of large (~200 kb) double-stranded DNA viruses, the 
orthopoxvirus genera includes VARV, MPXV, vaccinia virus (VACV), and mousepox’ 
(ectromelia virus, ECTV).  In general, the highly conserved center of the genome houses the 
genes essential for replication; whereas, the more variable ends of the genome contain genes 
important for virus-host interactions.  This large genomic capacity enables the 
orthopoxviruses to encode multiple proteins devoted to modulating the host’s immune 
system, in addition to the many proteins required for their cytoplasmic replication cycle. 
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To initiate infection, the virus binds to the host cell via an unidentified receptor, and 
a membrane fusion event releases the viral core into the cytoplasm (Figure 1-1) [5].  The 
complete transcriptional system packaged in the virion synthesizes the initial mRNAs to 
produce the enzymes required for DNA replication and transcription and anti-immune 
defense molecules, including a complement regulatory protein.  DNA replication is followed 
by transcription and translation of the intermediate and late mRNAs.  A single genome is 
packaged and matures into intracellular mature virus (IMV).  IMV is either released from the 
cell during lysis or enveloped by a Golgi membrane to form intracellular enveloped virus 
(IEV).  The IEV rides the microtubules to the plasma membrane where it acquires an actin 
tail and the outer membrane surrounding the virion fuses with the plasma membrane to 
release extracellular enveloped virion (EEV).  Some of these virions remain associated with 
the cell: the cell-associated enveloped virus (CEV).  Incomplete understanding of the 
function of each of the multiple infectious forms (IMV, EEV, and CEV) complicates the 
study of orthopoxvirus infection [6-8]. 
Ectromelia Infection 
 
ECTV infects mice in the wild.  While it replicates in most types of mammalian cells in tissue 
culture, its host-range is narrowly restricted to rodents [5].  The natural route of infection is 
thought to be via skin abrasions, which is most commonly mimicked in the laboratory by 
inoculating the footpad [9,10].  Following replication at the site of inoculation, the virus 
migrates to the draining lymph node, and replication there generates a primary viremia that 
seeds the liver, spleen, and other organs (Figure 1-2).  Replication in these organs generates a 
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secondary viremia that leads to foci of infection in distal organs including the skin.  The 
primary lesion develops at the inoculation site after approximately a week.  Several days later, 
certain susceptible mouse strains develop the characteristic cutaneous pox lesions for which 
these viruses are named [10].  The footpad or subcutaneous route of inoculation enables the 
study of early events during the course of poxvirus infection (Figure 1-2, days 0-3), stages at 
which the innate immune system predominates in the host’s response [11].  
Because of the array of inbred and genetically manipulated mouse strains available, 
the ECTV model offers much promise for analyzing the role of individual components of 
the immune response to poxvirus infection in a natural host.  Inbred mouse strains with 
differing degrees of susceptibility to ECTV provide a basis for determining the host factors 
that influence susceptibility to poxviruses [11].   
ECTV infection is 100% lethal in the susceptible strains BALB/c, DBA/2, and A/J 
[12].  In the A/J strain, the infection and necrosis of the spleen and liver is so severe that the 
mice die 7–8 days post-infection before the primary lesion develops [13].  In contrast, the 
resistant strain, C57BL/6, has an asymptomatic infection that is cleared from the footpad by 
day 18 post-infection [11,12]. Direct comparisons of the immune response in sensitive and 
resistant strains have associated resistance with induction of a strong type 1 cytokine 
response (including interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and interleukin-2) 
and a robust cytotoxic lymphocyte (CTL) response [12].   
Crossing C57BL/6 mice with susceptible DBA/2 mice and then selecting those 
animals with decreased susceptibility identified several resistance to mousepox (rmp) loci.  The 
rmp-1 locus on chromosome 6 mapped to the natural killer (NK) gene complex, which is 
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consistent with NK cells’ role in protection [14,15].  Another allele, rmp-2, mapped near 
complement component C5.  In preliminary experiments, passive transfer of C5 into a 
DBA/2 mice promotes lymphocyte recruitment to the spleen with histology similar to that 
observed in the resistant strain [16].   
Resistant strains of mice carrying specific genetic deficiencies have helped define the 
requirements for a protective immune response, including both the timely clearance of 
infection and survival (Table 1-1).  Similar to the observations from comparing sensitive and 
resistant mouse strains, antiviral cytokines and CTL responses are crucial.  For example, lack 
of IFN-γ [17-20], perforin [19-22], or CD8+ T cells [23,24] in a normally resistant background 
results in 100% mortality even with low inoculums.  Mice deficient in macrophages, toll-like 
receptor 9 [25], or NK cells [14,26] also have increased mortality during the acute infection.  
Mice lacking either granzyme A or B have a mild increase in mortality, but a lack of both 
results in 100% mortality with a mean time to death slightly greater than that of the perforin-
deficient mice [19,27].  Along the same line, mice deficient in either TNF receptor, p75 or 
p55, have increased morbidity (p75 > p55); however, the lack of both receptors results in a 
more severe phenotype with very early morbidity at two days post-infection [28].  Infection 
of mice that cannot produce inducible nitric oxide synthase 2 is uniformly lethal at higher 
doses despite the fact that the mice generate normal IFN-γ and CTL responses [29].  In 
contrast, mice lacking MHC-II, B cells, CD40, or CD40 ligand (CD154) survive the acute 
infection but eventually succumb approximately 2 weeks to 2 months post-infection 
[19,20,23].  Depletion of CD4+ T cells did not increase mortality; however, it impaired viral 
clearance at 21 days post-infection, particularly from the skin [24]. 
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Complement 
The complement system is an ancient system of host defense with the central molecules 
established more than one billion years ago based on their presence in cnidarian coral [30].  
In mammals, the system consists of around 30 serum and cell-associated proteins that 
interact to initiate or regulate a proteolytic cascade, similar to the clotting cascade, that 
mediates the powerful effector mechanisms of complement [31].  Hepatocytes synthesize 
most of the soluble proteins of the complement system; however, other cell types, such as 
epithelial cells, endothelial cells, monocytes, and other leukocytes also produce many 
components [32,33].  The complement system is central to the innate immune system and 
enhances the activity of the humoral arm of the adaptive response [34].   
Three distinct pathways activate the complement cascade: classical, lectin, and 
alternative (Figure 1-3) [31].  C1q, as part of the C1 complex, traditionally binds to the Fc 
portion of IgM and IgG antibody to trigger the classical pathway.  C1 also directly binds a 
variety of alternate ligands: viral glycoproteins, bacteria, and host proteins including, C-
reactive protein and SIGN-R1, which interact with microbes [35-37].  Mannan-binding lectin 
(MBL) or ficolins recognize repetitive carbohydrate motifs on the surface of pathogens and 
infected cells and activate complement similar to C1q [38,39].  Spontaneous turnover of C3 is 
believed to initiate the alternative pathway on foreign surfaces that lack complement 
regulatory proteins [35,40].  Recent reports demonstrate that properdin binds to pathogens 
and directs assembly of the alternative pathway C3 convertase, in addition to its traditional 
role stabilizing this convertase [41].  The three pathways converge at the step of C3 cleavage 
and share a common terminal pathway leading to formation of the membrane attack 
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complex (MAC).  Regardless of the initiating pathway, C3b produced by the C3 convertase 
deposits on surfaces and initiates a positive feedback loop by forming additional C3 
convertases through the alternative pathway.   
This proteolytic amplification cascade attacks invading microorganisms and diseased 
host cells through opsonization and lysis [35,40].  Due to its destructive potential, the host 
tightly regulates this system by expressing soluble and membrane-bound complement 
regulatory proteins [42].  Multiple human diseases have been linked to deficiencies in either 
enhanced activation or impaired regulation of the complement system [31].  Insufficient 
regulation results in excessive activation, leading to undesirable inflammation and tissue 
damage.  A functional deficit in complement regulatory proteins causes paroxysmal nocturnal 
hemoglobinuria and predisposes to atypical hemolytic uremic syndrome, glomerulonephritis, 
and age-related macular degeneration [43-46].   
 Human deficiencies in complement activation fall into two categories.  Deficiency of 
a component early in the pathway (C1-C4) predisposes to infections with pyogenic bacteria 
as well as autoimmune diseases; whereas, deficiency of a terminal pathway component (C5-
C9) is most commonly associated with increased susceptibility to bacterial infections, 
especially Neisseria [47].  Evidence derived from both patients and animal models has 
implicated complement as an essential part of host defense against multiple virus families 
[48-54].   
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Complement in Viral Infection  
Complement system activation can exert multiple antiviral effects (Figure 1-3) [35,55,56].  
Opsonization of the virion may block attachment or promote destruction by phagocytosis.  
The MAC disrupts the membrane integrity of the virion or virally infected cells.  The 
anaphylatoxin cleavage products, C3a and C5a, attract and activate proinflammatory and 
immune effector cells, as well as enhance epithelial resistance to viral infection [57].  Finally, 
complement activation induces and instructs the adaptive response and serves, along with Fc 
receptors, as an effector arm of antibody [56,58-60].   
Complement activation increases neutralization of virus by natural antibody, which is 
predominantly of the IgM isotype [60-63].  Natural IgM can effectively trigger the classical 
pathway, and this synergy between two arms of the innate immune system helps protect the 
host until the development of specific antibodies [60,64].  Natural antibodies are low affinity, 
polyreactive, and present in sera at relatively low titers [64,65].  Not only does natural 
antibody protect the host by preventing the dissemination of invading pathogens through the 
bloodstream, but it also helps induce the immune response by targeting antigen to the spleen 
[64,66].  These functions improve survival in mouse models of vesicular stomatitis virus 
infection and sepsis (cecal ligation and puncture) [66,67].  Natural antibody is mainly 
produced by B-1 cells, which reside predominantly in the peritoneum and pleura [64].  In the 
well-studied model of influenza infection, both the natural IgM present before infection from 
B-1 cells and the IgM produced in response to the infection by B-2 cells are required for 
survival [68].  This natural IgM requires complement activity to neutralize influenza in vitro 
[62].   
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Optimal activation of antibody and T cell responses depends on the workings of the 
complement system [56,58-60].  Early T cell-independent antibody responses to vesicular 
stomatitis virus require C3 and C4 [63].  Complement deficiency reduces the activation of 
CD4+ T cells and the subsequent ability to induce T cell-dependent antibody responses to 
influenza and West Nile viruses [50,69].  Proper CD8+ T cell responses to these two viruses 
and lymphocytic choriomeningitis virus are also complement-dependent [50,69,70].  Many 
leukocytes synthesize complement proteins, and the C3 produced by wild-type myeloid cells 
transplanted into C3-deficient mice enables normal induction of protective antibody 
responses to peripheral herpes simplex virus infection [33,71].  This indicates that 
complement’s impact on the adaptive immune response may result from local production 
and activation or may only require a low concentration (compared to serum levels) of 
complement proteins such as in tissue sites and body secretions.   
To evade complement’s activities, viruses use multiple strategies to hinder 
complement activation [40,55,56,72].  Viruses incorporate the host’s complement regulatory 
proteins into their envelopes or upregulate these proteins on the infected cell’s surface [73-
77].  Some virally infected cells avoid classical pathway activation by shedding or internalizing 
antibodies that bind their surface [78].  More commonly, viruses produce their own 
complement regulatory proteins to protect themselves.  Some of these proteins are unique to 
the virus [79,80], while others have structural and functional homology to the host’s own 
regulators [49,81].  The multiple strategies that viruses have developed to evade complement 
provide further evidence of this system’s importance in antiviral defense. 
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Viral Neutralization by Complement  
Complement-mediated neutralization occurs when activation exceeds the viruses’ ability to 
protect themselves.  In vitro experiments have demonstrated neutralization in the absence of 
specific antiviral antibody for multiple viruses: parainfluenza virus [75], influenza virus [62], 
simian virus 5 and mumps virus [82], West Nile virus [51], human immunodeficiency virus 
[83], vesicular stomatitis virus [84], and vaccinia virus [76,85,86].  Several mechanisms 
mediate neutralization in vitro.  For example, alternative pathway-initiated C3b deposition on 
two closely related paramyxoviruses results in the aggregation of simian virus 5, while mumps 
virus is lysed by engagement of MAC [82].  Even low concentrations of antiviral antibodies 
added to naïve sera increase neutralization and greatly expand the group of viruses sensitive 
to complement.  Along the same lines, removing or blocking the viruses’ complement 
defense strategies enhances neutralizing activity.  Natural antibody can initiate neutralization 
of herpes simplex virus that lacks glycoprotein C, a complement regulatory protein that lacks 
homology to the host regulators [87].   
Poxviral Inhibitors of  Complement Enzymes 
Complement regulatory proteins use three mechanisms to control complement activation: 
decay accelerating activity (DAA) dissociates the subunits that comprise the C3 and C5 
convertases (Figure 1-4A), cofactor activity (CA) irreversibly inactivates the convertases when 
C3b or C4b are proteolytically cleaved by factor I (FI) (Figure 1-4B), and irreversible binding 
of inhibitors blocks MAC insertion and formation [35].  Most cells protect their membranes 
by expressing complement regulatory proteins, including DAF (decay accelerating factor; 
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CD55) and MCP (membrane cofactor protein; CD46), which regulate the C3 convertases 
using either DAA or CA, respectively (Figure 1-4).  These proteins economically target the 
C3 and C5 convertases, as this is the step where the three initiating pathways converge 
(Figure 1-3).   
The poxvirus inhibitors of complement enzymes (PICEs) have approximately 35% 
homology to host regulatory proteins [88].  The PICEs are composed of 4 complement 
control protein repeats (CCP), like their human homologues MCP and DAF.  Historically, 
the most thoroughly studied proteins in this family are vaccinia complement control protein 
(VCP) and inflammation modulatory protein (IMP) from cowpox (CPXV) [89,90].  Recent 
studies by our laboratory and others have defined many of the regulatory properties of 
smallpox inhibitor of complement enzymes (SPICE) and monkeypox inhibitor of 
complement enzymes (MOPICE) [91,92].  
VCP:  VCP was the first secreted microbial protein identified as having a role in 
immunomodulation [90].  Using a combination of DAA and CA, VCP inhibits the classical 
(CA & DAA) and alternative (CA only) pathways [86,88,93,94]. VCP also prevents 
complement’s enhancement of antibody-dependent neutralization of IMVs by both the 
classical and alternative pathways [86].  Function-blocking antibodies to VCP restore 
complement’s ability to enhance neutralization [85,86].  The ability to bind and regulate C3b 
requires all four CCPs [95,96].  VCP attaches to the cell surface through a covalent linkage 
between its unpaired N-terminal cysteine and the viral protein A56 [97].  This mechanism 
may mediate VCP’s inclusion in EEVs, since A56 is also present [98].  A fraction of VCP 
(~5-30%) released from cells infected in vitro forms a disulfide linked dimer, via that same N-
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terminal cysteine, that possesses enhanced regulatory activity [99].  The multiple heparin 
binding sites present may influence the function and localization of VCP in vivo [96,100-104].   
IMP:  Culture supernatants from CPXV infected cells protect sensitized erythrocytes 
from complement activation and hemolysis in a dose dependent manner [105].  This protein 
has been studied more in vivo than in vitro (see below)[106]. 
SPICE:  SPICE resembles VCP in that it has CA against both pathways, has DAA 
for the classical pathway C3 and C5 convertases, binds heparin, and a proportion of it exists 
as a dimer [91,92,107].  SPICE differs from VCP by only 11 amino acids (Figure 1-5), but 
these changes enhance SPICE’s DAA by ~5-10 fold and CA by more than 100 fold for the 
human complement system [91,92,107,108].   
MOPICE:  Despite lacking most of CCP-4, MOPICE retains functional activity and 
dimerizes through an unpaired cysteine in the residual CCP-4 (Figure 1-5) [99].  It has 
~1/100 of SPICE’s CA, similar to VCP.  Unlike SPICE and VCP, MOPICE lacks DAA for 
either pathway, which implicates CCP-4 as being essential for DAA [91,92]. 
EMICE:  The ECTV genome demonstrated a homologue to SPICE and VCP, 
ectromelia inhibitor of complement enzymes (EMICE) [109].  As illustrated in (Figure 1-5), 
EMICE differs from SPICE by only 26 amino acids.  Interestingly, 40% of the amino acid 
differences between EMICE and SPICE as well as a contiguous two amino acid deletion 
occur in CCP-1, while SPICE and VCP have an identical CCP-1.  The remainder of EMICE, 
CCPs 2–4, resembles VCP more than SPICE, with 7 and 15 amino acid differences, 
respectively.   
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Poxviruses and Complement in vivo 
The initial experiment that examined the role of a PICE in vivo used VACV that lacked VCP 
(∆VCP-VACV).  The lesions produced by ∆VCP-VACV upon injection into the back of 
rabbits or C4-deficient guinea pigs were smaller than those induced by wild-type VACV [86].  
In a mouse model, similar experiments compared the IMP-deficient virus (∆IMP-CPXV) to 
its parent virus following footpad inoculation.  In contrast to the earlier results, ∆IMP-CPXV 
resulted in greater inflammation (swelling, induration, and mononuclear infiltrates) and tissue 
damage (hemorrhage) [105].  One interpretation of these data is that, in the case of ∆VCP-
VACV, the increased complement activation was able to control the infection earlier 
resulting in less tissue destruction; in ∆IMP-CPXV infection, the additional complement 
activation, either directly or indirectly (via the increased inflammatory infiltrate), damaged the 
tissue.  VCP and IMP likely use similar mechanisms to prevent complement activation and 
reduce inflammation, thereby protecting the virus (illustrated by ∆VCP-VACV) and its local 
environment (illustrated by ∆IMP-CPXV).   
CPXV infection of complement-deficient mice suggests a role for complement in the 
host response.  C5-deficient mice infected in the footpad with wild-type CPXV showed 
significantly greater induration, hemorrhage, and ulceration compared to the congenic C5-
sufficient strain [89,105].  One of two studies also measured greater edema in the C5-
deficient strain [89].  In the second study, equivalent edema occurred in both strains, and not 
only with the wild-type CPXV but also with ∆IMP-CPXV [105].  These results indicate that 
IMP affects the level of edema independent of C5 activity.  Similarly, C3-/- mice developed 
greater inflammation than the control mice following infection with wild-type CPXV [110].  
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In contrast, if infected with ∆IMP-CPXV, the C3-/- mice had slightly less inflammation than 
the wild-type mice.  As prior experiments showed, ∆IMP-CPXV induced greater 
inflammation than CPXV in wild-type mice, but the two viruses induced comparable 
responses in the C3-/- mice.   
Finally, the mapping of one of the genetic resistance alleles to ECTV to the region of 
the chromosome that contains C5 suggests that the complement system may have a role in 
protecting C57BL/6 mice [15,16].  The C5-deficient susceptible mouse strain, DBA/2, did 
not efficiently recruit lymphocytes to the site of infection.  Preliminary data described in one 
paper indicated that passive transfer of C5 into this strain changed lymphocyte targeting so 
that it resembles that seen in the resistant strain, C57BL/6 [16].   
In subsequent chapters, the impact of the complement system on ECTV infection 
will be investigated in vivo using complement-deficient mice.  The interaction between ECTV 
particles and mouse complement will be investigated in vitro.  Finally, the viral complement 
regulator, EMICE, will be characterized.  
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Figures 
Figure 1-1: Poxvirus replication cycle 
To initiate infection, the virus binds to the host cell via an unidentified receptor, and a 
membrane fusion event releases the viral core into the cytoplasm [5].  The complete 
transcriptional system packaged in the virion synthesizes the early mRNAs to produce 
immune defense molecules and the enzymes required for DNA replication and transcription.  
DNA replication is followed by transcription and translation of the intermediate and late 
mRNAs.  A single genome is packaged and matures into the IMV.  IMV is either released 
from the cell during lysis or enveloped by a Golgi membrane to form IEV.  The IEV rides 
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the microtubules to the plasma membrane where it acquires an actin tail and the outer 
membrane surrounding the virion fuses with the plasma membrane to release EEV.  Some 
of these virions remain associated with the cell (cell-associated enveloped virus, CEV.  
Incomplete understanding of the function of each of the multiple infectious forms (IMV, 
EEV, and CEV) complicates the study of orthopoxvirus infection [6,7].  
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Figure 1-2: Ectromelia infection in a susceptible mouse strain 
Following entry through a break in the skin, the virus replicates and disseminates to 
the draining lymph node.  Replication at the initial site and in the draining lymph node 
generates the primary viremia that infects the spleen and liver.  Virus released from these 
target organs causes a secondary viremia, which seeds distal sites like the skin.  The primary 
lesion develops at the entry site after approximately a week.  Several days later, certain 
susceptible mouse strains develop the characteristic cutaneous pox lesions for which these 
viruses are named [10].  Figure modified from Chung Lee.   
Day 0
Day 1
Day 2
Day 3-4
Day 4-5
Day 6
Day 7
Swollen 1°Lesion
Ulceration    Day 11
Early Rash Day 9
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Figure 1-3: Complement activation pathways 
The classical, lectin, and alternative pathways each initiate the complement cascade by 
forming a C3 convertase that cleaves C3 to C3b.  The binding of C1q to antibody triggers the 
classical pathway.  The carbohydrate motifs on pathogens activate the lectin pathway through 
MBL.  The classical and lectin pathways form the C4 containing convertase, C4b2a.  C3 
deposited by either of these two pathways or from spontaneous activation of C3 initiates the 
alternative pathway.  Upon binding to C3b, factor B (FB) is cleaved to Bb by factor D (FD), 
which forms the alternative pathway convertase, C3bBb.  The alternative pathway amplifies 
C3b deposition initiated by any pathway.  C3 activation leads to important antiviral effector 
19 
functions.  Release of the anaphylatoxins C3a and C5a recruits inflammatory cells.  C3b and 
C4b opsonize viral particles or infected cells, leading to neutralization or destruction by 
phagocytosis.  C3b also leads to activation of C5 and formation of the MAC, which disrupts 
virions or infected cells.  Complement activation is nature’s adjuvant to trigger the adaptive 
immune response.   
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Figure 1-4: Complement regulatory activity 
(A) Decay Accelerating Activity: the regulator binds to the C3 and C5 convertases and 
displaces the catalytic subunits. 
(B) Cofactor Activity: the cofactor protein binds to C3b or C4b and recruits factor I to cleave 
the protein and irreversibly inactivate the convertases. 
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Figure 1-5: Homology of the Poxviral Inhibitors of Complement Enzymes (PICEs)  
Color code: blue, differing residues; red, conserved cysteines; green star, putative heparin 
binding site (K/R-X-K/R).  A frame-shift mutation in CCP-4 of MOPICE produces a 
truncated protein.   
 
 
  
CCP1:SPICE  CCTIPSRPINMKFKNSVETDANANYNIGDTIEYLCLPGYRKQKMGPIYAKCTGTGWTLFNQCIKRR
VCP
MOPICE Y --
IMP                     G                                               K
EMICE                 N G  DT-- KV      V           S  V    N
CCP2:SPICE  CPSPRDIDNGHLDIGGVDFGSSITYSCNSGYYLIGEYKSYCKLGSTGSMVWNPKAPICESVK
VCP              Q H    S    E           E
MOPICE           Q                    H    S    E           E
IMP              QI     E             Q    S    E  Y        E
EMICE            Q T              Q    S    E           E
CCP3:SPICE  CQLPPSISNGHNGYNDFYTDGSVVTYSCNSGYSLIGNSGVLCSGGEWSNPPTCQIVK
VCP      S           E                                 D
MOPICE   S           E   I   I                 M
IMP     PS   VT      E                        IV       D
EMICE    S E E              V             D

CCP4:SPICE  CPHPTILNGYLSSGFKRSYSYNDNVDFTCKYGYKLSGSSSSTCSPGNTWQPELPKCVR-
VCP       S                    K                     K    
MOPICE     ISNGKLLAA---------------------------------------------
IMP        S T             H        RH
EMICE        S                  K                 E K      E
Fig. 6  
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Table 1-1: Effect of genetic or induced deficiency on ECTV infection in resistant 
mouse strains 
 
fp, footpad; iv, intravenous; in, intranasal; D, day post-infection.   
Deficiency Mortality Route Day of Death Reference 
CD8 100% fp 8-10 [23,24] 
β2m (Lack MHC I) 100% fp 14-18 [19,24] 
NK Cells 80-100% fp 7-10 [14,26] 
Perforin 100% fp 4-10 [19-22] 
Granzyme A & B 100% fp 8-11 [19,27] 
IFN-γ  100% fp 3-8 [17-20] 
     
Nitric oxide synthase 2 100% iv 6-8 [29] 
Macrophages 100% fp 8.5± 0.5 [24] 
TLR9 100% in 7-9 [25] 
TNFR  p55 & p75 60% fp 10-18 [28] 
     
MHC-II  100% fp 12-35 [19,20] 
µMT   100% fp 14-30 or ~60 [19,20,23] 
CD40  100% fp 40±16 [23] 
CD154  100% fp ~40 [23] 
Depletion of CD4+   0% at D21 fp  [24] 
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Chapter 2 
Multiple complement pathways required to 
survive ectromelia virus infection 
 
 
 
 
 
 
 
 
 
 
 
Portions of the chapter are excerpted from: 
Moulton E.A., Atkinson J.P., and Buller R.M.  (2008)  Surviving mousepox 
infection requires the complement system.  PLoS Pathogens.  In Press. 
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Introduction 
To better understand the virulence of smallpox, investigators have turned to related 
poxviruses like ectromelia virus (ECTV), the causative agent of mousepox.  Variola virus and 
ECTV have a narrow host-range and cause significant morbidity and mortality [3,4].  The 
numerous available mousepox-susceptible and -resistant mouse strains allow the components 
of the protective immune response to poxviruses to be dissected in the natural host. 
Disease severity varies among inbred mouse strains, and comparisons of these strains 
have elucidated factors essential for survival.  Mice naturally acquire ECTV via cutaneous 
abrasions, which is most commonly mimicked experimentally with footpad inoculation [4]. 
Through this route, ECTV infection is 100% lethal in susceptible strains (BALB/c, DBA/2, 
and A/J) but asymptomatic in the resistant C57BL/6 strain.  The C57BL/6 strain has a 
stronger TH1 type cytokine response and a more robust cytotoxic lymphocyte response than 
susceptible strains [5].  Lethal infection occurs in C57BL/6 mice that lack CD8+ T cells [6,7], 
B cells [7,8], macrophages [6], natural killer (NK) cells [9,10], interferon (IFN)-γ [11-13], IFN 
α/β receptor [13], perforin [14,15], and granzyme A or B [16].  Survival, therefore, requires 
both the adaptive and innate immune response. 
The innate immune system defends the host during the early phase of an infection 
and shapes the adaptive response [17-19].  The complement system is an essential 
component of the innate immune system, and evidence from human disease and animal 
models implicates complement as a critical part of host defense against several virus families 
[20-24].   
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Complement influences poxviral infections, but an essential role for survival has not 
been demonstrated.  One study described increased inflammation at the inoculation site of 
cowpox virus in C5-/- mice; however, no mortality occurred in these mice [48].  Additionally, 
an allele for genetic resistance to ECTV mapped to the chromosomal region containing C5 
[49].   
Using complement-deficient mice, the mousepox model offers an opportunity to 
characterize the role of this system during infection in the natural host.  Use of a model 
where the host and pathogen have co-evolved is particularly important given the species 
specificity of many poxviruses and of complement proteins, regulators, and receptors [3,50].  
In this study, we focused on the role of C3, the complement cascade’s central component.  
Resistant C57BL/6 mice that genetically lack C3 inadequately control ECTV infection and 
have increased morbidity, viral burdens, and mortality.  Similar increases in mortality were 
observed in FB- and C4-deficient mice, indicating a role for multiple complement activation 
pathways in protection.   
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Methods 
Virus production 
Plaque-purified Moscow strain ECTV was propagated in murine L929 cells.  Intracellular 
mature viral stocks were purified through a sucrose cushion as described [51] and titrated on 
BS-C-1 cells, an African green monkey kidney cell line [52].  Both cell lines were cultured in 
Dulbecco’s modified Eagle’s media (DMEM, BioWhittaker) supplemented with 10% heat-
inactivated fetal calf serum (FCS, HyClone), 2 mM L-glutamine, and antibiotics.   
Mice   
The following strains on a C57BL/6 background were acquired: C3-/- [53,54] and FB-/- 
[55,56] from H. Molina, Washington University Medical School; C4-/- [57] from M. Carroll, 
Harvard Medical School; and wild-type from Jackson Laboratories.  Age-matched mice of 
both sexes were used in the footpad and ear pinna studies (6–11 weeks-old).  Male mice were 
used in the intranasal (8–12 weeks) studies.  Some wild-type mice used in the footpad studies 
were purchased from Jackson Laboratories. The rest of the mice were bred at Washington 
University in a specific pathogen-free facility.  The animals were transported to the biohazard 
suite at Saint Louis University at least a week prior to infection.  All experiments were 
performed following the animal care guidelines of the two institutions. 
 In vivo studies  
Mice were inoculated with 10 µl ECTV diluted in PBS to the indicated dose using a 29 gauge 
insulin syringe into the ear pinna and hind footpad or a 20 µl pipettor for the intranasal route.  
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Mice were anesthetized for inoculation using CO2/O2 for the footpad route and 
ketamine/xylazine for the ear pinna and intranasal routes.  Individual mice were marked by 
ear punching or shaving.  After infection and before sacrifice in the mortality studies, mice 
were manipulated only to obtain weights.  Serum was collected from surviving animals at the 
end of the experiment.  The survival curves include only animals that generated an antiviral 
antibody response, which was detected by ELISA in >95% of the mice [58].   
Tissue titer 
Blood was collected via cardiac puncture.  Spleen and liver tissues were harvested aseptically, 
frozen immediately on dry ice, and stored at -70°C.  Tissues were homogenized in PBS-1% 
FCS to ~10% (weight/vol) using 1 ml glass homogenizers.  They were frozen and thawed 
three times, sonicated, and titrated on BS-C-1 monolayers [52].   
Viremia analysis 
DNA was isolated from whole blood collected in EDTA microtainer tubes (BD) using the 
High Pure PCR Template Preparation Kit (Roche).  The kit’s whole blood protocol was used 
with the following modifications.  The 40 µl Proteinase K, 200 µl Binding Buffer, 150 µl 
PBS, and 50 µl of whole blood in EDTA were added sequentially and then vortexed.  The 
incubation at 70°C was extended to 12 min.  The sample was applied to the column by 
centrifugation at 8,000 g for 2 min and eluted in 50 µl.   
Quantitative PCR was performed on viral DNA using Power SYBR Green PCR 
Master Mix on a 7500 Real Time PCR System (Applied Biosystems, Foster City, CA) [59].  
The primers (10 pmol) SP028 (GTAGAACGACGCCAGAAT AAGAATA, 5' at 120627 
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bp) and SP029 (AGAAGATATCAGACGATCCACAATC, 5' at 120462 bp) were used to 
amplify 165 bp of gene EV107.  The amplification product cloned into a plasmid vector 
(pGEM-T, Promega) was used as a standard to estimate copies of DNA/µl in blood.  Three 
to four wells were used for each sample. 
Histology 
Tissue samples were fixed in 10% buffered formalin, embedded in paraffin, sectioned, and 
stained with hematoxylin and eosin by the Digestive Diseases Research Core Center, 
Washington University.  The number of inflammatory foci and the magnitude of tissue 
necrosis were evaluated in blinded samples.  Inflammatory foci in a 10× visual field were 
counted for ~7 fields/mouse liver.   
Liver enzymes  
AST and ALT levels were measured in samples of frozen sera by the Department of 
Comparative Medicine at Saint Louis University using a standard clinical analyzer.  
Statistical analysis 
All statistical analysis was performed using GraphPad Prism software version 5.01 
(GraphPad Software, San Diego, CA).  The survival curves were analyzed by the log-rank 
test.  The Mann-Whitney test was used to determine the statistical significance of the viral 
titers, viremia, liver histology, and liver enzymes.   
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Results 
C3 deficiency increased morbidity and mortality of  ECTV inoculated by 
multiple routes 
The route of infection influences the interaction between poxviruses and the host [60].  Half 
of the 16 mutant vaccinia viruses assessed using two routes of inoculation, ear pinna and 
intranasal, had a detectible phenotype by only one route.  ECTV infections of C57Bl mice by 
the intranasal, intraperitoneal, or intravenous routes result in severe disease and mortality, 
while the footpad and intradermal routes cause minimal disease [61].  To examine the role of 
complement in vivo, wild-type and C3-/- mice were infected by three routes: footpad, ear 
pinna, and intranasal.   
Approximately 95% (54 of 57) of the wild-type mice survived when inoculated with 
40,000 pfu of ECTV, the highest dose employed in the footpad infections (Figure 2-1A).  In 
contrast, C3-/- mice had about 90% mortality at that dose.  They also had significantly 
increased mortality (P<0.0001) at lower doses, even if inoculated with only 4 pfu.  The 
median time to death increased as the dose decreased from 7 days at 40,000 pfu to 9, 10, or 
13 days at the lower doses of 4,000, 400, or 4 pfu, respectively.   
The C3-/- mice also showed increased morbidity over the course of the infection.  
Unlike the wild-type mice on day 7 post-infection with 40,000 pfu, the C3-/- mice displayed 
clinical signs of infection, including fur ruffling and hunchbacked posture.  Consistent with 
these observations, C3-/- mice lost more weight at 400 and 40,000 pfu than wild-type (Figure 
2-1B). The few surviving C3-/- mice at the 400 pfu dose required ~3 additional weeks, 
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compared to the wild-type mice, to return to their initial weight.  All surviving mice in Figure 
2-1A were held for at least 40 days to monitor recovery, and a subset of C3-/- mice (n=4 at 
400 pfu) were held to day 119 post-infection.  The mice that survived the acute illness 
steadily recovered weight and showed no signs of relapse. 
The ear pinna studies used a dose of 700 pfu to mimic the low inoculum thought to 
transmit the natural poxvirus infection [2].  The infection caused 72% mortality in the C3-/- 
mice (28 of 39) (Figure 2-1C), compared to 25% in the wild-type mice (6 of 24, P=0.0002).  
The surviving C3-/- mice lost less weight and recovered to the initial weight earlier with 
inoculation by the ear pinna compared to the footpad route (Figure 2-1B & D).  In contrast 
to the increased morbidity and mortality observed, C3 deficiency caused no gross differences 
in the primary lesion; C3-/- and wild-type mice had similar levels of footpad swelling or 
necrosis at the ear pinna inoculation site (data not shown). 
To examine the role of C3 in intranasal infection, the dose was lowered to 100 pfu 
due to the increased susceptibility of the wild-type mice with this route.  C3 deficiency 
increased the mortality rate from 40% to 80% (P<0.0001, Figure 2-1E).  Similar to the other 
routes, the surviving C3-/- mice had more severe disease than wild-type, as they had greater 
weight loss and took longer to recover (Figure 2-1F).   
C3 deficiency resulted in earlier dissemination of  ECTV to the target 
organs, higher peak viral titers, and delayed viral clearance 
ECTV replicates at the inoculation site and in the draining lymph node to generate the 
primary viremia that infects the spleen and liver [4].  Virus released from these target organs 
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causes a secondary viremia, which seeds distal sites like the skin to generate the characteristic 
pox lesions. 
To begin to dissect how C3 contributed to protection against ECTV, we examined 
viral burden in two key tissues, the spleen and liver.  Wild-type and C3-/- mice were 
inoculated in the footpad with either 400 or 40,000 pfu, and then spleen and liver tissue were 
collected on day 7 post-infection.  All animals had detectible virus in either the spleen or 
liver.  At the two doses, the C3-/- mice had a 1-2 log higher mean titer than wild-type mice in 
both tissues (Figure 2-2A & B).   
In wild-type mice, both doses produced similar maximal tissue titer; however, the 
higher dose increased the uniformity of the group and, thereby, increased the mean titer.  At 
the 40,000 pfu dose, the splenic viral burden in the C3-/- mice was ~150-fold higher 
(P=0.0002, Figure 2-2A).  Reducing the dose to 400 pfu resulted in ~25-fold lower viral titer 
in the C3-/- mice, yet it was still ~25-fold higher than the wild-type controls (P=0.03).  In 
contrast, both doses produced similar liver titers in the C3-/- mice.  The lower dose revealed 
an 80-fold increase in the liver titer of the C3-/- mice compared to the wild-type mice 
(P=0.01, Figure 2-2B), while the higher dose showed less of a difference between the strains 
(15-fold) due to the increased titer in the wild-type mice.  Illustrative of the impact of C3, the 
C3-/- mice at 400 pfu had higher titers than the wild-type mice given 40,000 pfu, a 100-fold 
more virus. 
These increases in viral titer prompted further exploration of how C3 deficiency 
impacts viral spread.  C3 could control viral replication early at the inoculation site by directly 
inactivating free virus or by recruiting inflammatory cells through release of anaphylatoxins.  
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The lack of C3 in the blood to neutralize or opsonize the virus could also result in greater 
viremia, thereby producing the higher titers observed in the target organs on day 7.  
Alternatively, C3’s well-established ability to facilitate induction of antibody and T cell 
responses could explain the observed difference [21,22,54,62-65].  To elucidate when the 
infections in the C3-/- and wild-type mice diverge, we inoculated via the ear pinna route and 
examined the viral burden in the blood, spleen, and liver on days 2, 4, 7, and 10 post-
infection.  The ear pinna route was selected for further analysis because it is a cutaneous 
route of inoculation that mimics a natural infection of the epithelium, where complement 
may promote containment.  
Using whole blood enables an unbiased detection of all virus, whether free in the 
plasma or in infected cells.  Quantitative PCR was employed to detect viral DNA in blood on 
days 2, 4, and 7 (Figure 2-2E).  A few day 2 samples contained viral DNA, but most were 
below the detection limit.  The C3-/- mice had 2.0- and 2.5-fold higher levels of viral DNA 
than wild-type mice had on days 4 and 7 (P=0.004 and 0.03, respectively). 
Despite the low levels of viremia on day 2, infectious virus was present in the spleen 
of over 70% of the C3-/- mice (13 of 18) compared to 28% of the wild-type mice (5 of 18, 
P=0.006, Figure 2-2C).  By day 7 post-infection, the C3-/- mice had 45-fold higher viral titers 
in the liver (P=0.01, Figure 2-2D), and there was also a similar trend in the spleen (6-fold, 
P=0.09).  The wild-type mice regained weight starting on day 10 (Figure 2-2-1D), and by then 
over 80% had cleared the virus from the spleen or liver (9 of 11, Figure 2-2C & D).  In 
contrast, less than half of the C3-/- mice survived to day 10 (Figure 2-1C), and of these, over 
75% had ongoing infection of the spleen and liver (7 of 9, P=0.008 & 0.01, respectively).   
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In summary, C3 deficiency resulted in earlier dissemination to spleen and in higher 
peak titers in the liver.  The viral infection also continued to day 10 in the C3-/- when it had 
been cleared by most wild-type mice. 
C3 deficiency increased hepatic inflammation and necrosis 
In susceptible mouse strains, ECTV causes extensive hepatic and splenic necrosis [66,67].  
We compared C3-/- and wild-type mice for histopathological changes in the liver on days 4, 7, 
and 10 post-infection. 
On day 4, the liver histopathology appeared normal in 4 of 5 wild-type and 3 of 4  
C3-/- mice (data not shown).  By day 7, all animals had a diffuse lymphocytic infiltrate in 
addition to discrete inflammatory foci (Figure 2-3).  These lesions varied in size and were 
smaller and less frequent in the wild-type (Figure 2-3A & B) compared to the C3-/- mice 
(Figure 2-3C & D).  They often occurred near the portal triad, and some contained areas of 
coagulative necrosis.  An inflammatory infiltrate encircled the discrete necrotic foci (Figure 2-
3B & C) and bordered the areas of bridging necrosis (Figure 2-3D).  In contrast to the liver, 
no major differences were observed in the spleen at this time (data not shown).  Using 
blinded samples, we counted the necrotic and non-necrotic foci and evaluated the location 
and severity of the necrosis in the liver (Figure 2-4). 
There were prominent differences between the C3-/- and wild-type mice relative to 
the number inflammatory foci and in the degree of necrosis.  The C3-/- mice had twice as 
many total foci (8 vs. 18 per field, P=0.02, Figure 2-4A) and 5-fold more foci containing 
regions of necrosis (3 vs. 15 per field, P=0.03, Figure 2-4B).  The majority of inflammatory 
foci contained necrotic areas in two-thirds of the C3-/- mice compared to only one-fifth of 
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the wild-type mice (Figure 2-4C).  The C3-/- mice had larger foci with more extensive necrosis 
(P=0.02, Figure 2-4D).  Most wild-type mice had small foci with either no necrosis or only 
piecemeal necrosis (0 & 1 on necrosis severity scale, Figure 2-3A & B, respectively).  In 
contrast, the C3-/- mice had confluent areas of necrosis that coalesced into bands of bridging 
necrosis (2 & 4 on the necrosis severity scale, Figure 2-3C & D, respectively).  Given that 
necrosis most frequently occurred in zone 1 of the liver, it likely originated there and then 
extended into zones 2 and 3 (Figure 2-4E).  
The increased hepatic necrosis in the C3-/- mice resulted in higher levels of liver 
enzymes, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), in the serum 
on day 7 (P=0.008, 0.0503, respectively, Figure 2-4F).  The AST and ALT levels positively 
correlated with the viral burden (Figure 2-4G).   
Most C3-/- mice died between day 7 and 10 (Figure 2-1C).  Two C3-/- mice that were 
sacrificed on day 10 had ~5-7 inflammatory foci per field, while the 5 wild-type mice had 
only occasional foci (data not shown).  At this time point, infectious ECTV persisted in the 
C3-/- mice; whereas, wild-type mice had cleared the infection (Figure 2-2D). 
Surviving ECTV infection required multiple complement pathways 
To examine the importance of the classical and lectin vs. alternative pathways in vivo, we 
compared C4-/- and FB-/- mice to C3-/- and wild-type mice.  We challenged C4-/- mice via the 
ear pinna route and monitored survival and weight loss.  Over 90% of the C4-/- mice 
succumbed to the infection (P<0.0001, Figure 2-5A).  The C4-/- and C3-/- mice had 
comparable mortality and weight loss (Figure 2-5C & 2-1D).   
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Intranasal ECTV infection also produced similar results in the C3-/-, C4-/-, or FB-/- 
mice.  Each complement-deficient strain had a higher mortality rate compared the wild-type 
mice (P<0.0001), and there were no significant differences among the three strains       
(Figure 2-5B).  The complement-deficient strains also lost weight at a similar rate         
(Figure 2-5D & 2-1F).  Thus, control of ECTV in vivo required both the alternative and 
classical pathways. 
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Discussion 
We investigated the impact of complement deficiency using the ECTV mouse model.  
Specifically, C3 deficiency permitted ECTV to disseminate earlier, reach a higher viral titer in 
the target organs, and induce greater liver damage.  Deficiency of C3, C4, or FB resulted in 
acute lethal infection, establishing a requirement for multiple complement pathways in host 
defense against this pathogen.   
The ECTV model system provides several advantages for analyzing the role of 
complement in poxviral pathogenesis.  First, the mouse-specific pathogen ECTV has 
coevolved with and causes severe disease in the natural host, analogous to variola virus in 
humans.  Second, the role of complement and the pathways involved can now be more 
rigorously dissected in vivo and in vitro with the availability of complement-deficient mice.  
Third, viral pathogenesis, morbidity, and mortality can be assessed by multiple routes of 
infection and across a range of viral inoculum to demonstrate a broad requirement for 
complement.   
Complement-deficient mice succumbed to acute ECTV infection with the majority 
of deaths occurring between days 6-10.  Based on time to death following footpad 
inoculation (Table 1-1), C3 deficiency resembled immunodeficiencies of other important 
components of the antiviral response, specifically CD8+ T cells [6,7], NK cells [9,10], and 
IFN-γ [12].  In contrast, mice deficient in CD4+ T cells [6], CD40, or CD40 ligand (CD154) 
[7] survive the acute phase but do not clear the virus.  The CD40-/- and CD154-/- mice 
ultimately die ~4 to 8 weeks post-infection.  This differs from surviving C3-/- mice, which 
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recovered and did not show signs of ongoing illness for up to 4 months of observation.  The 
early death of the complement-deficient mice highlights the complement system’s essential 
contribution to survival during the first few days of infection.   
To characterize how complement protects the host from lethal infection, we 
analyzed the impact of C3 deficiency on the kinetics of viral spread.  ECTV replication at the 
inoculation site and in the draining lymph node produces a viremia that seeds the primary 
target organs, the liver and spleen [4].  Several observations from this study increase our 
understanding of complement’s role in controlling poxviral infection.   
First, as early as day 2, C3 deficiency allowed for greater spread of ECTV from the 
inoculation site to the spleen.  This indicates that complement is a key player in the initial 
hours of infection, likely to control ECTV at the inoculation site.  Second, we detected 
higher levels of viral DNA in the blood on days 4 and 7, which establishes that C3-/- mice 
poorly control viral dissemination through the bloodstream.  This higher viremia could result 
from increased replication in tissues and/or decreased clearance of virus from the 
bloodstream.  Third, the liver viral titers on day 7 were ~50-fold higher in the C3-/- mice.  
The greater viremia likely produced more extensive infection, but a delayed adaptive immune 
response may also have contributed to this observation.  The viral titer correlated with serum 
levels of ALT, which suggests that ECTV caused hepatic necrosis either directly through lytic 
infection or indirectly through the antiviral immune response.  An inflammatory infiltrate 
surrounded the necrosis in the C3-/- mice, which contrasts with susceptible Balb/c mice 
where necrosis occurs in the absence of a lymphocytic infiltration [68].  In summary, we 
propose that mice lacking C3 have reduced ability to control ECTV locally and in the 
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bloodstream, leading to higher levels of infection greater tissue damage in the liver, and 
mortality.   
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Figures 
Figure 2-1: C3 deficiency increased mortality and morbidity in C57BL/6 mice 
(A, C, & E)  Greater mortality was observed in C3-/- compared to wild-type (WT) C57BL/6 
mice by multiple routes of inoculation.  The number of animals in each group is to the right 
of the line, and the statistics compare the survival of C3-/- and wild-type mice.   
(B, D, & F)  C3-/- mice have increased morbidity following infection by the indicated route as 
monitored by weight loss.  Weight loss for individual animals was normalized to their starting 
weight, and mean±SEM is shown.  The graph segregates the mice that survived the infection 
(filled symbols) from those that succumbed (open symbols).  The number of animals in each 
group is presented at the end of the line.   
 (A & B)  Mice were inoculated in the footpad with the dose listed to the right of the survival 
curve or in the legend.  The survival curves were generated from 2 or 3 separate experiments 
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(except for a single experiment at 4,000 pfu).  The survival of the C3-/- mice significantly 
differed from the wild-type mice at all doses (P<0.0001).  (B)  The one C3-/- mouse that 
survived at 40,000 pfu is not shown for clarity.  C3-/- mice alive at day 49 continued to gain 
weight until day 119 post-infection. 
(C & D)  Mice were inoculated with 700 pfu ECTV via the ear pinna.  The data are 
combined from four separate experiments. (P=0.0002).   
(E & F)  Mice received 100 pfu of ECTV intranasally.  The curves are generated from at least 
seven separate experiments (P<0.0001). 
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Figure 2-2: C3 deficiency promoted earlier dissemination to and increased viral titers 
in the target organs 
C3-/- and wild-type mice were infected by the footpad or ear pinna route and sacrificed on 
day 2, 4, 7 or 10 post-infection.  The viral titer of the spleen (A, C) or liver (B, D) was 
determined by direct plaque assay and is expressed as the log10 plaque forming units (PFU)/g 
tissue.  The level of viral DNA in whole blood was measured using quantitative PCR (E).  
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The scatter plots show the viral burden of each wild-type (WT, black, ) and C3-/- (red, ) 
animal.  The error bars indicate SEM.  The wild-type and C3-/- mice were compared, and P 
values <0.05 are reported above the bracket.  The dotted line represents the limit of 
detection for the assay. 
(A, B)  Mice were infected with 400 or 40,000 pfu of ECTV in the footpad and sacrificed on 
day 7 post-infection.  At 400 pfu, all animals had virus detected in either the spleen or liver. 
(C-E)  Animals were infected with 700 pfu of ECTV via the ear pinna.   
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Figure 2-3: Extensive liver necrosis occurred in C3-deficient mice 
Liver samples were taken from mice 7 days after infection with 700 pfu via ear pinna, fixed, 
sectioned, and stained with hematoxylin and eosin.  Representative images show the range of 
differences between the strains.  White lines border coalesced areas of necrosis.  Arrowheads 
point to non-necrotic inflammatory foci.  T, portal triad; V, central vein.   
(A)  Wild-type—Blood flows through the liver from zone 1 to 3, as indicated by the arrow.  
Zone 1 encircles the portal triad; zone 3 encircles the central vein, and zone 2 occurs 
between zones 1 and 3.  There are small inflammatory foci adjacent to two portal triads. 
53 
(B)  Wild-type—There are inflammatory foci adjacent to portal triads, and one focus has a 
small area of confluent necrosis. 
 (C)  C3-/-— Larger inflammatory foci with areas of confluent necrosis. 
 (D)  C3-/-—An inflammatory infiltrate borders the extensive necrosis that bridges across all 
three zones (TV). 
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Figure 2-4: C3-deficient mice had a greater number of inflammatory foci with more 
extensive necrosis 
(A-F) Wild-type (WT, black, ) and C3-/- (red, ) mice were compared, and P values are 
above the bracket.  Error bars are SEM. 
(A) The number of inflammatory foci/visual field was counted.  Each point represents the 
mean from ~7 fields for an individual mouse.  The graph plots the mean number of foci for 
each animal. 
(B)  The number of inflammatory foci containing necrosis was counted and displayed as 
described in (A). 
(C)  The percentage of foci that contained areas of necrosis. 
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(D)  The severity of the necrosis was quantitated using a 0-4 scale: 0, none; 1, piecemeal 
necrosis; 2, confluent areas of necrosis; 3, confluent areas of necrosis that extend beyond a 
single zone; and 4, bridging necrosis.   
(E)  The zones of the liver (1, 2, & 3) where necrosis occurred.  Zones are described in 
(Figure 2-3A).   
(F)  The serum levels of the liver enzymes in uninfected mice were <100 for AST and <50 
for ALT. 
(G)  AST (blue) and ALT (black) levels positively correlate with liver viral titer (r2=0.54 and 
0.69, respectively).  The log of these parameters for both C3-/- and wild-type mice was used 
for linear regression. 
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Figure 2-5: Deficiency of classical or alternative pathway components reduces 
survival 
(A & C)  C4-/- mice have greater mortality than wild-type (WT, P<0.0001).  C4-/- mice were 
compared to C3-/- and wild-type mice following inoculation with ~ 700 pfu ECTV via the ear 
pinna.  Weight loss for individual animals was normalized to their starting weight, and 
mean±SEM is shown.  The weights of the surviving animals (filled symbols) are separated 
from those that succumbed (open symbols).  The number of animals in each group is at the 
right of the line.  The data combine four separate experiments.   
(B & D)  Increased mortality in C4-/-, FB-/-, and C3-/- mice compared to wild-type 
(P<0.0001).  Mice received 100 pfu intranasally.  Data are displayed as described above.  
Curves are generated from multiple experiments (n for C4=6, FB=4, C3=7, WT=8).  The 
surviving FB-/- mouse was omitted from (D) for clarity.  
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Chapter 3 
Mouse complement neutralizes ectromelia 
intracellular mature virus 
 
 
 
 
 
 
 
 
 
 
 
Portions of the chapter are excerpted from: 
Moulton E.A., Atkinson J.P., and Buller R.M.  (2008)  Surviving mousepox 
infection requires the complement system.  PLoS Pathogens.  In Press. 
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Introduction 
The complement system consists of cell-surface and serum proteins that interact to destroy 
invading microorganisms and infected host cells [1-4].  Three distinct pathways activate this 
cascade: classical, lectin, and alternative.  Antibody binding to antigen triggers the classical 
pathway.  Mannan-binding lectin (MBL) and related proteins recognize repetitive 
carbohydrate motifs on pathogens and infected cells to initiate the lectin pathway [5].  
Spontaneously activated C3 initiates the alternative pathway, especially if deposited on 
surfaces deficient in regulatory proteins [6].  The alternative pathway also serves as a positive 
feedback loop by forming additional C3 convertases from the C3b produced by any pathway.  
In the absence of essential activating components, the slower and less efficient bypass 
pathways can activate the classical and lectin pathways at high serum concentrations [7].  All 
three pathways converge at the step of C3 cleavage to C3a and C3b, and they share a 
common terminal pathway that generates the C5a anaphylatoxin and the membrane attack 
complex (MAC).   
Complement activation could delay viral dissemination by opsonizing or lysing, and 
thereby neutralizing, virions at the inoculation site or in the circulation and by promoting the 
inflammatory response, including the recruitment of phagocytic cells.  To assess if 
complement could directly neutralize ectromelia virus (ECTV), we examined the interaction 
between purified ECTV and mouse complement in vitro.  Our in vitro and in vivo evidence 
suggests that the complement system, in the presence of natural antibody, neutralizes ECTV 
early in infection and contributes to survival. 
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Methods 
Virus production 
Plaque-purified Moscow strain ECTV was propagated in murine L929 cells.  Intracellular 
mature viral stocks were purified through a sucrose cushion as described [8] and titrated on 
BS-C-1 cells, an African green monkey kidney cell line [9].  Both cell lines were cultured in 
Dulbecco’s modified Eagle’s media (DMEM, BioWhittaker) supplemented with 10% heat-
inactivated fetal calf serum (FCS, HyClone), 2 mM L-glutamine, and antibiotics.   
Mice    
The following strains on a C57BL/6 background were acquired: C3-/- [10,11] and FB-/- 
[12,13] from H. Molina, Washington University Medical School; C4-/- [14] from M. Carroll, 
Harvard Medical School; B cell-deficient µMT [15] from H. W. Virgin, Washington 
University Medical School; C1q-/- [16] from M. Botto, Imperial College School of Medicine; 
FD-/- [17] from Y. Xu, University of Alabama, Birmingham; and MBL A-/- × MBL C-/- 
(B6.129S4-Mbl1tm1Kata Mbl2tm1Kata/J) and wild-type from Jackson Laboratories.  The 
C5+/+ and C5-/- C57BL/10 mice (B10.D2-Hc1 H2d H2-T18c/nSnJ, B10.D2-Hc0 H2d H2-
T18c/oSnJ) were also obtained from Jackson Laboratories. Age-matched mice of both sexes 
were used in the µMT survival experiments (10-11 weeks-old).  Male µMT mice were used in 
the sera transfer (10-12 weeks) studies.  Some wild-type and µMT mice were purchased from 
Jackson Laboratories. The other mice were bred at Washington University in a specific 
pathogen-free facility.  The animals were transported to the biohazard suite at Saint Louis 
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University at least a week prior to infection.  All experiments were performed following the 
animal care guidelines of the two institutions. 
 In vivo studies  
Mice were inoculated with 10 µl ECTV diluted in PBS to the indicated dose using a 29 gauge 
insulin syringe into the hind footpad.  Mice were anesthetized for inoculation using CO2/O2.  
Individual mice were marked by ear punching or shaving.  After infection and before 
sacrifice in the mortality studies, mice were manipulated only to obtain weights.  In the 
passive transfer experiment, mice received intraperitoneally 1 ml of wild-type or µMT 
C57BL/6 sera on day -1 and 0.5 ml every two days starting on day 0.   
Complement neutralization assay 
 Mouse EDTA plasma and sera were collected on ice from male C57BL/6 mice in 
microtainer tubes (BD), separated by centrifugation, and then pooled, aliquoted, and frozen 
at -70°C.  Plasma and sera were diluted on ice into GVB± Ca++/Mg++ (B102, B103, 
Complement Technology) or GVB without Ca++/Mg++ (GVB°), respectively, to 2× the 
desired final concentration (vol/vol).  Purified ECTV was sonicated and diluted in PBS 
(without Ca++/Mg++) to ~5 × 104 pfu/ml.  A 1:10 dilution in the buffer used to dilute the 
complement source, GVB±Ca++/Mg++, produced a final concentration of 5 pfu/µl.  An 
equal volume of virus (30 µl≈150 pfu) was added rapidly to the diluted complement at RT.  
Samples were vortexed, centrifuged for 5 sec, and incubated at 37°C for 60-90 min.  Samples 
were diluted by addition of 700 µl of DMEM-2% FCS, vortexed, and applied to BS-C-1 
monolayers in 6-well plates.  After 1 h, 3 ml/well of 37°C overlay media                            
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(1% carboxymethylcellulose in culture media) was added.  After 3-5 days, the cells were fixed 
with 1 ml/well of an 11% formaldehyde / 0.13% crystal violet / 5% ethanol solution for 
over 1 h, rinsed, and dried.  The number of plaques was scored visually using a light box.  
The EDTA plasma or sera data were normalized to the buffer only control or heat-
inactivated sera, respectively. 
Statistical analysis 
All statistical analysis was performed using GraphPad Prism software version 5.01 
(GraphPad Software).  Either 1-way ANOVA followed by Tukey multiple comparisons test 
or 2-way ANOVA was used for the analysis of the complement neutralization assays.  The 
survival curves were analyzed by the log-rank test.   
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Results 
Mouse complement neutralized ECTV intracellular mature virions  
To explore the interaction between C3 and ECTV in vivo, we examined how mouse 
complement affects ECTV virions in vitro.  Purified intracellular mature virus (IMV) was 
incubated with either EDTA-treated plasma or sera from naïve C57BL/6 mice.  Infectious 
virus was detected as plaques on a BS-C-1 monolayer.  EDTA-treated plasma was 
reconstituted with a buffer containing calcium and magnesium to allow for complement 
activation.   
Reconstituted wild-type plasma neutralized approximately 90% of the virus (Figure 3-
1A, P<0.001).  Heat inactivation or buffer lacking calcium and magnesium abolished 
neutralization.  Wild-type sera concentrations of 10, 25, or 50% neutralized 70-80% of the 
ECTV (Figure 3-1B, P<0.0001).  These observations implicate the complement system in 
neutralizing ECTV. 
Classical pathway initiated neutralization 
To further define how complement neutralized ECTV, sera from mice genetically deficient 
in complement components or antibody were used (Figures 3-2F).  The neutralizing activity 
was reduced by ~50% with deficiency of either C3 or C4 (Figure 3-2A).  Mixing C3-/- and   
C4-/- sera produced results equivalent to wild-type sera.   
This requirement for C4 for full ECTV neutralization was further dissected.  The 
C1q subunit of C1 interacts with antibody to trigger the classical pathway.  MBL, a C1q 
analog, initiates the lectin pathway.  MBL A-/- × MBL C-/-, C1q-/-, and antibody-deficient 
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(µMT) sera were compared (Figure 3-2B).  µMT or C1q-/- sera only partially neutralized 
ECTV, comparable to C4-/- sera.  Conversely, wild-type levels of neutralization occurred 
independent of MBL A and C.  These data establish that natural antibody activated the 
classical complement pathway to neutralize ECTV.   
µMT sera neutralized ECTV when combined with natural antibody 
Further analysis revealed three key points relative to natural antibody.  First, heat-inactivated 
wild-type sera behaves like buffer alone, which indicates that natural antibody alone lacks 
neutralizing activity; instead, complement activity was required to neutralize ECTV       
(Figure 3-1A & 3-2E).  Second, heat-inactivated wild-type sera, as a source of natural 
antibody, restored the neutralizing activity of µMT sera (Figure 3-2C).  Consistent with this 
finding, µMT or heat-inactivated wild-type serum did not effectively neutralize ECTV 
independently, but they did so in combination.  Third, the modest but significantly greater 
neutralization in the normal compared to heat-inactivated µMT sera suggests that antibody-
independent (alternate pathway) complement activation also occurred.  
Alternative pathway contributed to neutralization 
C3b deposited by any pathway can then interact with factor B (FB) and factor D (FD) to 
generate the alternative pathway C3 convertase, which amplifies C3b production (positive 
feedback loop).  Alternative pathway activation itself likely explains the neutralization 
observed in the µMT, C1q-/-, or C4-/- sera.  FB-/- or FD-/- sera neutralized less ECTV than 
wild-type sera (Figure 3-2D), which indicates that the alternative pathway enhanced 
complement-mediated neutralization initiated by the classical pathway.   
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Opsonization neutralized most ECTV, but lytic activity also had a role 
C3b could neutralize ECTV by directly preventing attachment to or entry into the cell or by 
disrupting the virion’s membrane through formation of the C5 convertase and the MAC.  
C5b initiates the terminal pathway that forms the MAC, and no lytic activity occurs in the 
absence of C5.  C5-/- sera from C57BL/10 mice were used to define the contribution of the 
MAC to neutralization (Figure 3-2E).  C5-/- sera neutralized a significant portion of virus 
(P<0.001), however, less than C5+/+ sera (P<0.05).  These findings suggest that opsonization 
by C4b and C3b mediated most of the neutralization; although, the MAC also contributed.   
To conclude, these findings demonstrate that naïve wild-type mouse sera neutralized 
ECTV.  We propose that natural antibodies bound to ECTV and triggered the classical 
pathway.  This led to C4b deposition, formation of the C3 convertase, and C3b deposition 
on the virus.  The alternative pathway amplified the C3b placed on the virion by the classical 
pathway.  Most ECTV neutralization occurred through opsonization by C4b and C3b, with a 
minor contribution from the MAC.   
Natural antibody delayed mortality in µMT mice 
Complement poses a barrier to the systemic spread of pathogens, particularly through the 
bloodstream [18].  The major role of complement could be to neutralize ECTV upon 
recognition by natural antibody.  Our prior experiments established that B cell-deficient µMT 
mice challenged with a high dose of ECTV by the footpad route all died early in infection 
(94% by day 8) (Figure 3-3A).  Their early death suggests that B cells contribute to survival 
prior to the rise of specific antibody on day 7 [19].   
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Based on our in vitro data and the data of others [20,21], we hypothesized that natural 
antibody is primarily responsible for this early protection.  Consequently, providing µMT 
mice with natural antibody should prolong their survival.  Based on the work of Ochsenbein 
et al. [21], µMT mice infected with a high dose of ECTV were treated with naïve sera from 
either µMT or wild-type mice (Figure 3-3B).  Treatment with wild-type sera increased the 
median day of death from 7 to 9; however, sera lacking natural antibodies (µMT) had no 
effect.  On day 8 post-infection, over half of the mice receiving wild-type sera outlived both 
other groups and 16 of 17 mice from the prior experiments (Figure 3-3C).  Thus, natural 
antibody delayed, but did not prevent, lethal ECTV infection in µMT mice. 
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Discussion 
Naïve plasma or sera neutralized ECTV in a complement-dependent manner, even at a 
concentration as low as 10%.  Sera from mice deficient in specific complement components 
demonstrated that maximal neutralization required both the classical and alternative 
pathways.  µMT sera, lacking antibody, resembled the sera deficient in the classical pathway 
components, C1q or C4, and addition of natural antibody restored neutralization activity.  
Opsonization led to neutralization of the majority of viral particles; however, the modest but 
significant difference between the C5-/- and C5+/+ sera indicated that the MAC also 
contributed to viral damage.  Interestingly, no complement component deficiency tested fully 
abolished neutralization.  The residual activity suggests that the classical and alternative 
pathways functioned independently, likely because both C4b and C3b opsonized and, 
consequently, neutralized ECTV.  However, the system was most effective when the two 
pathways and the MAC worked cooperatively.   
The reconstitution of the neutralization activity in the µMT sera with heat-inactivated 
wild-type sera suggests that natural antibody is important in the neutralization process.  
Consistent with this observation and prior studies with other viruses [20,21], natural antibody 
passively transferred into µMT mice lengthened survival during the acute infection.  In our 
experiments, most µMT mice died early, with 100% mortality by day 9 at the highest 
inoculum.  The mice that survived the acute infection eventually died at about 2 months 
post-infection. Our findings differ from prior studies, which described mortality at either 2-4 
weeks [22] or 2 months [23] post-infection.  More of our mice survived the acute infection at 
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the lower doses. This suggests that the observed discrepancy could be secondary to 
differences in the viral stock or dose, as both differed among the three groups.  The death of 
the µMT mice, despite natural antibody treatment, indicates that B cells help control the 
infection by additional mechanisms.   
Our in vitro experiments provide a model for understanding the fate of the viral 
inoculum in our in vivo experiments, since they both used the same stock of purified IMV.  
To understand the spread of infection, a second infectious form must be considered.  During 
viral replication in the host cell, extracellular enveloped virus (EEV) is produced by 
enveloping the IMV with an additional unique membrane derived from the Golgi complex 
and late endosomal compartment (Figure 1-1)[24].  In studies of vaccinia virus, the host’s 
complement regulators, present in the outermost membrane, protect the EEV from human 
and rabbit complement; in contrast, the IMV is sensitive to complement [25].  Our study 
builds on this observation by determining the contribution of each complement activation 
pathway to the neutralization of IMV infectivity, and it implicates natural antibody as the 
primary initiating factor [21].  We also show that natural antibody by itself is ineffective and 
requires augmentation by the complement system to neutralize ECTV.  Additionally, the 
neutralization observed with vaccinia virus and ECTV points to the IMV form being 
inherently susceptible to complement-mediated neutralization.   
The relative importance of IMV vs. EEV during infection in vivo is not well 
established.  However, the IMV’s sensitivity to complement neutralization suggests that 
ECTV likely travels through areas featuring efficient complement activation, such as the 
blood stream, in the EEV form or within infected cells.  At extravascular sites, where 
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complement levels are lower than in circulation, infected cells may produce sufficient soluble 
poxviral complement regulatory protein to protect the IMV.   
Most poxvirus disease models initiate infection with the complement-sensitive IMV.  
If complement activity in the mouse behaves as it does in vitro, then inoculated ectromelia 
IMV should be recognized by natural antibody and coated with C4b and C3b, resulting in 
neutralization of viral infectivity at the site of injection and inhibition of spread.  This line of 
reasoning could explain why the mortality increases in the wild-type mice as the invasiveness 
of the route decreases [26].  Percutaneous inoculation would likely result in neutralization, 
while application to the mucosal membranes might enable ECTV to enter host cells before 
being neutralized by complement.  Once internalized, ECTV produces its regulatory protein 
and EEV to evade complement and propagate the infection.  Additionally, based on the in 
vitro data, complement deficiency would greatly limit this initial neutralization, which likely 
contributes to the early spread and greater mortality observed in the complement-deficient 
mice.   
A sub-neutralizing concentration of complement opsonins could target the virion for 
immune adherence and phagocytosis in vivo, particularly in blood with its high complement 
levels.  Furthermore, the liver sinusoids are lined with Kupffer cells bearing CRIg 
(complement receptor of the Ig superfamily), which mediates phagocytosis of C3-opsonized 
pathogens [27].  Indeed, the liver clears over 95% of intravenously administered ECTV from 
the circulation within 5 min of injection [28].  In the following hour, most of the viral antigen 
in the liver becomes undetectable by immunofluorescence, and viral infectivity decreases by 
over 90%. This rapid removal suggests that the virus has been recognized as foreign and 
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tagged for immune adherence and phagocytosis.  Opsonization by complement followed by 
uptake via the recently described CRIg provides a mechanistic explanation for these 
important observations made nearly five decades ago [28]. 
These observations influence the interpretation of poxviral infections initiated with 
an IMV-rich inoculum by the intravenous route.  The liver’s Kupffer cells may sequester 
most of the inoculated virus within minutes and destroy much of it within an hour, thereby 
inhibiting systemic dissemination.  Not only is the dose effectively reduced by ~10-fold, but 
the neutralized IMV also provides the immune system with an immediate source of antigen.  
These issues have particular relevance for the monkeypox and variola virus non-human 
primate models that commonly use the intravenous route to test vaccines and antivirals for 
human use  [29-34].   
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Figures 
Figure 3-1: The murine complement system neutralizes ECTV virions 
(A-B)  ECTV was incubated with a mouse complement source at 37°C for 1 hour and then 
added to BS-C-1 monolayers.  The absolute number of plaques was normalized to the 
appropriate controls (white bars) to give the relative number of plaques.  Graphs display 
mean±SEM from multiple experiments.   
(A)  Mouse plasma neutralizes ECTV.  ECTV was combined with 10% wild-type (WT) 
mouse EDTA-treated plasma or heat inactivated (HI) plasma in gelatin veronal buffer in the 
presence or absence of calcium and magnesium (Ca/Mg). The active plasma (in the presence 
of Ca/Mg) differed from all other groups (***, P<0.001).  These data were combined from 9 
independent experiments using EDTA plasma collected on 3 separate days.  The total 
number of replicates for each column from left to right follows: n=25, 29, 17, 7, 3.  Data 
were analyzed using 1-way ANOVA followed by the Tukey multiple comparison test. 
(B)  Mouse serum neutralizes ECTV (***, P<0.0001) at multiple concentrations.  ECTV was 
incubated with increasing concentrations of HI (white) or active (black) WT mouse sera.  
77 
Data represent 3-4 independent experiments performed in duplicate with 4 different 
collections of sera.  A 2-way ANOVA was used to analyze concentration and activity.   
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Figure 3-2: Maximal neutralization requires multiple complement pathways 
The relative roles of the complement pathways were analyzed using sera from mice 
genetically deficient in complement components (C3, C4, C1q, MBL A × MBL C, FB, FD, 
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or C5) or antibody (µMT).  ECTV was incubated at a final concentration of 50% sera at 
37°C for 1 hour and then added to BS-C-1 monolayers.  The absolute number of plaques 
was normalized to heat-inactivated sera (HI, white bars) to give the relative number of 
plaques.  Graphs display mean±SEM from multiple experiments.  Data were combined from 
at least 2 experiments performed in duplicate with independent collections of sera.  All data 
were analyzed using 1-way ANOVA followed by the Tukey multiple comparison test, and 
any significant differences among grouped bars are noted on the graph.  Unless noted 
specifically below, the significant differences are displayed on the graph as follows: *, P<0.05;  
**, P<0.01; ***, P<0.001.   
(A)  C3-/- or C4-/- sera have reduced neutralizing capacity.  Combining C3-/- and C4-/- sera 
restored neutralizing activity to WT levels.  WT-HI differed from the other conditions (***).  
Data were from at least 3 experiments performed in duplicate. 
(B)  Deficiencies in the classical pathway (C4, C1q) and antibody (µMT), but not the lectin 
pathway (MBL), reduce neutralization.  WT-HI differed from C1q-/- (P<0.01) and differed 
from the rest of the conditions (P<0.001).  Data were from at least 2 experiments performed 
in duplicate.   
(C)  Neutralizing activity requires the alternative pathway components: factor B (FB), factor 
D (FD), and C3.  WT-HI differed from the other conditions (***).  Data were from at least 
two experiments performed in duplicate.   
(D)  Addition of either 10% or 25% WT-HI sera restores the neutralizing activity of 
antibody-deficient µMT sera to WT capacity.  Heat inactivation of µMT sera reduces 
neutralization.  Data were from 2 experiments done in duplicate.   
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(E)  MAC (C5b-9) formation enhances neutralization but is not required.  Both the C5+/+ 
and C5-/- sera had greater neutralization than HI-C5+/+.  The buffer only control (GVB°) is 
equivalent to WT-HI.  Data combined from 3 experiments performed in triplicate.   
(F)  The classical, lectin, and alternative pathways each initiate the complement cascade by 
forming a C3 convertase that cleaves C3 to C3a and C3b.  Antibody triggers the classical 
pathway through C1q.  The carbohydrate motifs on pathogens activate the lectin pathway 
through MBL.  The classical and lectin pathways form the C4 containing convertase, C4b2a.  
C3 deposited from these two pathways or from spontaneous activation of C3 initiates the 
alternative pathway.  Upon binding the activated C3 molecule, FB is cleaved to Bb by FD, 
which forms the alternative pathway convertase, C3bBb.  The alternative pathway amplifies 
the C3b deposited by any pathway.  C3 activation leads to important antiviral effector 
functions.  Release of the anaphylatoxins C3a and C5a recruits inflammatory cells.  C3b and 
C4b opsonize viral particles or infected cells, leading to neutralization or destruction by 
phagocytosis.  C3b also leads to activation of C5 and formation of the MAC which disrupts 
virions or infected cells. 
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Figure 3-3: Natural antibody delays mortality in µMT mice 
(A)  µMT mice are susceptible to ECTV via the footpad route.  µMT mice were challenged 
with ECTV, and a dose dependent increase in mortality was observed.  The 50,000 pfu dose 
differs from 5,000 pfu (P=0.006) and 500 pfu (P<0.0001), and the lower doses differ from 
each other (P=0.045).  Survival curves were constructed from 4 separate experiments, and 
the number of animals is to right of the legend.   
(B & C)  Treating µMT mice with natural antibody delays mortality.  µMT mice were 
challenged with high doses of ECTV (100,000 pfu) via the footpad route in two separate 
experiments.  Some mice received wild-type sera as a source of natural antibody, while others 
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received µMT sera (1 ml on day -1 followed by 0.5 ml on days 0, 2, 4, 6, 8, 10).  The 
untreated curve in (G) includes the historical control data from the untreated mice at 50,000 
pfu in (A).  The number of animals in each group is next the legend.   
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Chapter 4 
EctroMelia Inhibitor of  Complement Enzymes 
(EMICE) protects intracellular mature virus 
from neutralization by mouse complement 
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Introduction 
In their large double-stranded DNA genomes, poxviruses encode multiple factors that 
modify the immune system [1,2].  Study of these molecules has provided insights into the 
balance between viral pathogenesis and the host’s immune response [3-6].  Viruses have 
evolved multiple strategies to evade the complement system [7].  They may hijack the host’s 
complement regulatory proteins by incorporating them in their envelopes [8-11], binding 
them in the serum [12,13], or upregulating them on the infected cell’s surface [14].  In other 
cases, viruses produce their own complement regulatory proteins to protect themselves [15-
18].   
Variola virus, vaccinia virus, monkeypox virus, and ectromelia virus (ECTV) each 
produce an orthologous complement regulatory protein (poxviral inhibitors of complement 
enzymes, PICE) that has structural and functional homology to host proteins [19-24].  Like 
the host regulatory proteins membrane cofactor protein (MCP, CD46) and decay accelerating 
factor (DAF, CD55), the PICEs are composed of four complement control protein (CCP) 
domains except for MOPICE (monkeypox inhibitor of complement enzymes), which has a 
frame-shift mutation in CCP-4 that results in premature truncation.  The complete loss of 
MOPICE may account for the reduced virulence observed in the West African compared to 
Congo basin strains of monkeypox virus [24,25].  The limits of the monkeypox animal 
models, however, have made this a difficult hypothesis to test.  While PICE-deficient 
mutants have been generated in vaccinia and cowpox viruses, neither of the parent viruses 
causes a lethal infection in the tested models [20,26].  The loss of the regulatory protein 
resulted in smaller local lesions with vaccinia [20] and in greater inflammation in the case of 
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cowpox [26].  An incomplete understanding of the role of the complement system during 
poxviral infections complicates interpretation of these results.   
In vitro, the PICEs regulate complement activation through a combination of decay 
accelerating activity and cofactor activity.  The co-evolution of variola virus with its only 
natural host, humans, may explain the enhanced activity against human complement 
observed with SPICE (smallpox inhibitor of complement enzymes) compared to the other 
PICEs [19,27].  The most well characterized PICE is VCP (vaccinia virus complement 
control protein) [20,21,28-38].  Originally described as a secreted complement inhibitor [21], 
VCP also attaches to the surface of infected cells (in vivo and in vitro) through a covalent 
interaction with the viral membrane protein A56 [33].  The ability of VCP and SPICE to 
interact with cells through their heparin-binding sites is also well documented in vitro 
[23,30,31,35].   
In this study of the PICE produced by ECTV, the ability of EMICE (EctroMelia 
Inhibitor of Complement Enzymes) to regulate complement activation was assessed.  
Recombinant EMICE (rEMICE) reduced activation of both human and mouse 
complement.  Murine cells produced measurable EMICE 4–6 h post-infection.  The level of 
EMICE in the supernatant reached 1 µg/ml by 16 h, which is prior to the release of the 
majority of the complement-sensitive intracellular mature virus (IMV) from infected cells.  At 
a concentration of 1 µg/ml, rEMICE protected ECTV IMV from complement-mediated 
neutralization.   
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Methods 
rEMICE production 
Using EMICE cDNA (in pSG5) as a template, the coding sequence of EMICE was 
generated by PCR using the following primers: 5’- CCGGAATTCGGAATGTGCT 
GTACTATTCCGTCACG-3’ and 5’- ATAAGAATGCGGCCGCTTATTCGCGTACA 
CATTTTGG-3’.  The resulting PCR fragment was ligated into the EcoR1 and NotI sites of 
pET28a-2 [23], a derivative of pET28a (EMD/Novagen) generated in our laboratory.  For 
recombinant protein production, the following method was developed [23].  First, 25 ml of 
an overnight culture of E. coli containing the construct was inoculated into 500 ml of LB 
containing kanamycin (30 mg/ml) and chloramphenicol (34 mg/ml) and grown to an 
OD600 of 0.6–0.8 followed by induction with 1 mM isopropyl-β-D-thiogalactopyranoside at 
37°C for an additional 3–5 h.  Cells were harvested and pellets were frozen at -80°C until 
needed.  For inclusion body protein purification, pellets were thawed and resuspended in 50 
ml of solution buffer (50 mM Tris (pH 8.0), 25% sucrose, 1 mM EDTA, 0.01% NaN3,       
10 mM DTT) to which 0.8 ml of freshly prepared 50 mg/ml lysozyme (Sigma-Aldrich), 1250 
U of benzonase nuclease (Novagen), and 1 ml of 1 M MgCl2 were added.  An equal volume 
of lysis buffer (50 mM Tris (pH 8.0), 1% Triton X-100, 0.1 M NaCl, 0.01% NaN3,               
10 mM DTT) was added, and the solution was stirred gently at room temperature for 1 h.  
After cooling, the suspension was sonicated with three 15 s bursts (Fisher Scientific model 
500 Sonic Dismembrator) at 50% amplitude followed by the addition of 5 ml of 0.5 M 
EDTA.  The lysate was then centrifuged at 6000 × g for 30 min at 4°C.  The resulting 
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inclusion body pellet was washed (50 mM Tris (pH 8.0), 0.5% Triton X-100, 0.1 M NaCl, 1 
mM EDTA, 0.01% NaN3, 1 mM DTT) followed by a second wash with the same buffer but 
without Triton X-100.  For solubilization of the inclusion bodies, the pellet was resuspended 
in 6 M guanidine HCl, 10 mM Tris (pH 8.0), and 20 mM 2-ME and centrifuged at 14,000 × g 
for 10 min.  A second high-speed centrifugation at 100,000 × g for 30 min at 4°C was 
performed to remove any insoluble material.  For protein refolding, solubilized inclusion 
body protein was added dropwise in three injections over 36 h at a final concentration of 10–
100 µg/ml in refolding buffer (100 mM Trizma base, 400 mM L-arginine-HCl (Sigma-
Aldrich), 2 mM EDTA, 0.02 M ethanolamine, 0.5 mM oxidized glutathione (Sigma-Aldrich), 
and 5 mM reduced glutathione (Sigma-Aldrich)).  The refolding solution was concentrated in 
a Millipore stirred filtration cell followed by buffer exchange with 20 mM Tris (pH 8.0).   
EMICE quantification and detection 
rEMICE was quantified using carbonic anhydrase (C5024, Sigma) as a standard on a 
Coomassie-stained SDS polyacrylamide gel.  EMICE in tissue culture samples was compared 
to rEMICE via Western blotting [24].  Non-reduced and reduced samples were 
electrophoresed in 12% SDS-polyacrylamide gels (Invitrogen), transferred to nitrocellulose 
membranes, and probed with 1:5000 dilution of a previously described rabbit anti-VCP 
antibody [24] followed by HRP goat anti-rabbit IgG (GE Healthcare).  rEMICE was also 
detected via flow cytometry [23].  Cells were incubated with a 1:5000 dilution of rabbit anti-
VCP for 30 min at 4°C followed by FITC-donkey anti-rabbit IgG secondary antibody diluted 
to 1:100 for 30 min at 4°C (Sigma).  After washing, the cells were resuspended in 0.5% 
paraformaldehyde and analyzed with a BD Biosciences FACSCalibur system.   
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C3b and C4b binding assay  
Binding to C3b and C4b was detected using a previously described ELISA format [39].  
Briefly, wells were coated overnight at 4°C with human C3b or C4b (Complement 
Technologies, CompTech) diluted in PBS to 5 µg/ml followed by blocking for 1 h at 37°C in 
1% BSA, 0.1% Tween 20 in PBS.  EMICE was diluted in low salt ELISA buffer (10 mM 
Tris (pH 7.2), 25 mM NaCl, 0.05% Tween 20, 4% BSA, 0.25% Nonidet P-40) and incubated 
for 1.5 h at 37°C.  Wells were washed with low salt ELISA buffer between each step.  
Incubation with rabbit anti-VCP antibody diluted 1:5000 in low salt ELISA buffer for 1 h at 
37°C was followed by peroxidase-coupled donkey anti-rabbit IgG (Jackson 
ImmunoResearch) at 1:10,000 for 1 h at 37°C.  The 3,3´,5,5´-tetramethylbenzidine substrate 
was added, and the OD was determined at 630 nm.  Binding assays employed serially diluted 
samples in at least three separate experiments. 
C3b and C4b cofactor assay  
The cofactor assays were previously described [40].  In brief, biotinylated ligands were 
combined with human factor I (100 ng) and varying concentrations of the cofactor proteins 
in low salt cofactor buffer (10 mM Tris (pH 7.2), 25 mM NaCl, 1% Nonidet-P40).  Cleavage 
products were evaluated using 10% reducing gels (Invitrogen) followed by transfer and 
Western blotting with ExtrAvidin-HRP (E2886, Sigma).  Detection was with SuperSignal 
Substrate (34380, Pierce).  Assays were performed in duplicate at least three times.   
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Decay-accelerating assay 
Decay-accelerating assays for the classical pathway C3 convertase were performed as 
previously described [24] with modifications for reading absorbance via microtiter dishes.  
Briefly, Ab-coated sheep erythrocytes (EA, CompTech) were diluted in dextrose gelatin 
veronal buffer (DGVB++) to 1.7 × 108 cell/ml.  The cells were washed by centrifugation for 
5 min at 2000 × g and resuspended in DGVB++ between sequential incubations with the 
following human proteins (CompTech): C1 at 1 µg/ml for 15 min at 30°C, C4 at 2.2 µg/ml 
for 15 min at 30°C, and C2 at 0.25 µg/ml for 4 min at RT.  After a brief chilling on ice, the 
cells were washed and resuspended at 1.7 × 108 cell/ml in DGVB++.  To assess decay 
accelerating activity, 50 µl of inhibitor (diluted in DGVB++) was combined with an equal 
volume of prepared cells for 10 min at 30°C.  Subsequently, 250 µl of guinea pig serum 
(CS1662, Colorado Serum Company) diluted 1/20 in 40 mM EDTA-GVB (CompTech) was 
added and incubated for 30 min at 37°C.  After centrifugation for 3 min at 2000 × g, the 
supernatant was removed and the absorbance at 405 nm was determined.  Cells were 
incubated in distilled water to produce the 100% lysis control, while cells incubated only in 
buffer were the background control.  Assays were performed at least four times with each 
condition in duplicate.   
Complement challenge assay 
Chinese hamster ovary cells (CHO), the American Type Culture Collection CHO-K1 line, 
were obtained from the Washington University Tissue Culture Support Center.  They were 
cultured in Ham’s F12 medium supplemented with 10% heat-inactivated (HI) fetal calf 
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serum (FCS), 2 mM L-glutamine, 100 U/ml penicillin G, and 100 µg/ml streptomycin 
sulfate.   
The standard procedure for initiating the complement pathways [41] was modified to 
use mouse sera as the source of complement.  CHO cells (about 70% confluence) were freed 
using the cell detachment buffer (4mM EDTA (Sigma) and 10% HI-FCS in PBS) and 
collected and washed in PBS-1% FCS.  To allow rEMICE to bind the CHO cells, 1 × 106 
cells were mixed with 20 µg of rEMICE in a total volume of 100 µl in 96 well V bottom 
plate (1 × 106/well) and incubated at 30°C in an Eppendorf Thermomixer for 30 min (300 
rpm).  Following incubation, cells were placed on ice and washed with PBS-1% FCS.  The 
sensitizing antibody, IgG from rabbits injected with whole CHO cells (Harlan Bioproducts 
for Science), was added to the cells, and the mixture was incubated for 20 min at 4°C on a 
shaker (600 rpm).  The cells were centrifuged at 466 × g for 5 min; the supernatant was 
discarded.   
For complement activation, the cells were washed in 100 µl gelatin veronal buffer 
with Ca++/Mg++ (GVB++, G-6514, Sigma) and then resuspended in 50 µl GVB++.  An equal 
volume of freshly isolated mouse sera diluted into the same buffer to a 20% concentration 
was added and mixed thoroughly.  Mouse sera were collected in eppendorf tubes, clotted on 
ice for 30 min, and the supernatant was stored at 4°C until use.  After 45 min incubation at 
37°C (300 rpm) in the Thermomixer, the samples were washed with 100 µl of PBS-1% FCS.  
Cells were stained with a 1:100 dilution of FITC conjugated goat F(Ab’)2 fragment to mouse 
C3 (Cappel 55510) for 30 min at 4°C with shaking (600 rpm), washed in PBS-1% FCS, and 
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resuspended in 0.5% paraformaldehyde in PBS.  C3 deposition was detected by flow 
cytometry.   
Virus production and culture 
Plaque-purified Moscow strain ECTV was used to generate the EMICE-deficient virus 
(∆EMICE).  The left and right flanking segments of the EMICE gene (017) were selected to 
produce a central 600 bp deletion.  They were amplified by PCR using EVM 017 LF-5’ 
(GCGGGCGCCGTGGAGTTTATACCACGTATGAG) with EVM017 LF-3’ (GCGACG 
CATTGCGTCGACGCTAGCGGACGTGACGGAATAGTACAG) and EVM017 RF-5’ 
(GCGACCGTACTCGAGGCGGCCGCAAGCTTGATCATACTCATACAAGCACAAT
G) with EVM 017 RF-3’ (GCGGAATTCCGTATCTCCGACA AGCACGTAG) and then 
ligated into pNCEV017.  This plasmid was recombined into ECTV as previously described 
[42].  Briefly, six-well plates of CV-1 cells were infected with ECTV (2 × 107 pfu/well) and 
then transfected with 2 ng of pNCEV017 using Lipofectamine 2000 (Invitrogen).  After 48 
h, cell lysates were collected and isolates were subject to two rounds of plaque purification in 
the presence of mycophenolic acid followed by three rounds without mycophenolic acid.  
The EMICE gene was reintroduced to ∆EMICE using a similar protocol and a 10 kb PCR 
product from genomic DNA (23179–33190 bp).  Crude ∆EMICE stock (4 × 106) was 
combined with 2 µg psoralen, 120 µg bovine serum albumin, and DMEM to a total volume 
of 1 ml.  After 10 min incubation, the mixture was exposed to a UV lamp in a 6-well tissue 
culture plate and applied to a BS-C-1 monolayer.  The 10 kb PCR product and viral DNA 
from ∆EMICE were transfected with Lipofectamine 2000 at a 1:40 molar ratio.  The 
resulting virus was collected and subject to four rounds of plaque purification on BS-C-1 
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cells.  The deletion and restoration of EMICE was detected by PCR using the primers EVM 
017 LF-5’ and EVM 017 RF-3’ and confirmed by Western blotting.  Viral DNA was isolated 
from infected BS-C-1 cells, an African green monkey kidney cell line, using the DNeasy 
Blood and Tissue Kit (cultured cell protocol, Qiagen).   
Plaque-purified ECTV strains were propagated in murine L929 cells.  Intracellular 
mature viral stocks were purified through a sucrose cushion as described [43] and titrated on 
BS-C-1 cells [44].  A single stock of each virus was aliquoted, titrated, and used for all 
experiments.  Both cell lines were cultured in Dulbecco’s modified Eagle’s media (DMEM, 
BioWhittaker) supplemented with 10% HI-FCS (HyClone), 2 mM L-glutamine, and 
antibiotics.   
In the EMICE production studies, 24-well plates of L929 with 106 cells/well were 
infected at an MOI of 1 with ∆EMICE or +EMICE ECTV for 1 hr.  Each well was washed 
with 1 ml of 37°C DMEM two times.  Finally, 1000 µl of DMEM was added to each well, 
and this marked the 0 h time point.  At each time point, 800 µl of supernatant was collected 
for analysis, and the remaining supernatant was discarded.  The cell layer was washed two 
times with 1 ml DMEM; 100 µl of DMEM was added; the cells were scraped off, 
resuspended, and collected.  200 µl of supernatant was used to determine the viral titer.  At 
early times, 500 µl of supernatant was concentrated 10-fold in a Millipore concentrator unit 
(UFV5BCC25).  All samples were stored at -70°C.  Frozen samples were thawed, mixed 1:1 
with Laemmli Sample Buffer (Bio-Rad), boiled for 10 min, and transferred on dry ice to 
Washington University where they were analyzed by Western blotting.   
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Mice  
The following strains on a C57BL/6 background were acquired: C3-/- [45,46] and FB-/- 
[47,48] from H. Molina, Washington University Medical School; C4-/- [49] from M. Carroll, 
Harvard Medical School; B cell-deficient µMT [50] from H. W. Virgin, Washington 
University Medical School; C1q-/- [51] from M. Botto, Imperial College School of Medicine; 
FD-/- [52] from Y. Xu, University of Alabama, Birmingham; and MBL A-/- × MBL C-/- 
(B6.129S4-Mbl1tm1Kata Mbl2tm1Kata/J) and wild-type from Jackson Laboratories.  The 
C5+/+ and C5-/- C57BL/10 mice (B10.D2-Hc1 H2d H2-T18c/nSnJ, B10.D2-Hc0 H2d H2-
T18c/oSnJ) were also obtained from Jackson Laboratories. 
Complement neutralization assay 
 Mouse sera were collected on ice from male C57BL/6 mice in microtainer tubes (BD) and 
then pooled, aliquoted, and frozen at -70°C.  EMICE or a control protein was serially diluted 
1:10 in GVB without Ca++/Mg++ (GVB°, B103, CompTech) producing a final volume of 20 
µl.  Purified ECTV was sonicated and diluted in PBS (without Ca++/Mg++) to 5 × 104 
pfu/ml.  A 1:10 dilution in GVB° produced a final concentration of 5 pfu/µl.  Wild-type 
mouse sera were diluted to 60% in GVB°, and 10 µl of this was added to the protein 
containing tubes.  An equal volume of virus (30 µl≈150 pfu) was added rapidly to the diluted 
complement/protein at RT.  Samples were vortexed, centrifuged for 5 sec, and incubated at 
37°C for 2 min in water bath and for 60–90 min in an incubator.  Samples were diluted by 
the addition of 700 µl of DMEM-2% FCS, vortexed, and applied to BS-C-1 monolayers in  
6-well plates.  After 1 hr, 3 ml/well of 37°C overlay media (1% carboxymethylcellulose in 
culture media) was added.  After 3–5 days, the cells were fixed with 1 ml/well of               
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11% formaldehyde / 0.13% crystal violet / 5% ethanol solution for over 1 hr, rinsed, and 
dried.  The number of plaques was scored visually using a light box.  The data were 
normalized to the HI-sera control. 
In vivo studies  
Mice were anesthetized with ketamine/xylazine and inoculated intranasally with 10 µl ECTV 
diluted in PBS to the indicated dose using a 20 µl pipettor.  The 100 pfu experiments used 
male mice (8–12 weeks).  Wild-type male and female mice (10–12 weeks-old) received 500 
pfu or 250 pfu, respectively.  Individual mice were marked by ear punching or shaving.  After 
infection and before sacrifice, mice were manipulated only to obtain weights.  
Statistical analysis 
All statistical analysis was performed using GraphPad Prism software version 5.01 
(GraphPad Software, San Diego, CA).  The CHO complement deposition used an unpaired t 
test (two-tailed).  The EC50 was determined using non-linear regression (log(agonist) vs. 
normalized response—variable slope).  The survival curves were analyzed by the log-rank 
test. 
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Results 
Characterization of  rEMICE’s complement regulatory activity 
Similar to our previous work with recombinant PICEs (rVCP, rMOPICE, and rSPICE) 
[23,24], we produced rEMICE in E. coli and analyzed its regulatory activity.  Throughout 
these experiments, rEMICE was compared to rSPICE, a potent regulator of the human 
complement system that served as a positive control.  The regulation of the complement 
system by PICEs requires an ability to bind the key components of the C3 convertases, C3b 
and C4b.  rEMICE’s interaction with these two proteins was assessed using an established 
ELISA protocol [39].   
In the case of human C3b, rEMICE bound approximately 10-fold less than rSPICE 
(Figure 4-1A).  rSPICE has the highest affinity for C3b of the PICEs tested [24].  Upon 
comparison to published data, rEMICE’s binding ability most closely resembled that of 
rMOPICE and was greater than rVCP, which is about 100-fold less than rSPICE.  In 
contrast, rEMICE and rSPICE bound C4b similarly (Figure 4-1B).  The higher affinity for 
human C4b compared to human C3b was also observed for rMOPICE and rVCP [24].   
Given the efficient binding to C4b and previous reports of decay accelerating activity 
being mediated by the PICEs [24,27,34], we explored the ability of rEMICE to dissociate 
(decay) the human classical pathway C3 convertase (Figure 4-1C).  In this experimental 
method, the convertase (C4bC2a) was assembled on the surface of antibody-coated 
erythrocytes using purified human complement components.  The cellular intermediate was 
then incubated with the regulatory protein followed by C3 and the late components of the 
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complement system.  If the regulatory protein efficiently dissociates the convertases, then 
there is less hemolysis of the cells.  rEMICE decayed the human classical pathway C3 
convertase, being about 50% as active in this regard as rSPICE.   
In contrast to decay accelerating activity, cofactor activity permanently deactivates the 
convertases.  Factor I, in the presence of a cofactor like the PICEs, cleaves the α chain of 
C3b or C4b, and the resulting cleavage fragments can no longer form a convertase.  
rEMICE’s ability to serve as a cofactor protein was assessed by combining it with the 
protease factor I and biotinylated C3b or C4b.  Similar to rSPICE, rEMICE serves as a 
cofactor protein for the cleavage of C3b and C4b at concentrations as low as 3.3 ng/ml 
(Figure 4-1D), and no cleavage occurred in the absence of factor I.  
rEMICE bound CHO cells and protected against mouse complement  
The three heparin binding sites that mediate SPICE’s interaction with the surface of cells are 
present in EMICE [23,24].  Secreted EMICE could limit complement deposition on infected 
cells by binding to their surface.  Similar to rSPICE, rEMICE bound to CHO cells (Figure 4-
2A).  This enabled us to next assess how well rEMICE regulated mouse complement on a 
cell surface.   
CHO cells, with or without prior exposure to rEMICE, were mixed with an anti-
CHO antibody, and then mouse sera was added.  Flow cytometry was employed to measure 
the quantity of C3b deposited (Figure 4-2B).  Since the classical pathway was activated (wild-
type or FB-/- sera) by the antibody in this assay, it most closely mimics an infection process 
upon the production of specific antiviral IgG antibody.  In this setting, rEMICE did not 
impact C3 deposition.  However, if only the alternative pathway was activated (C4-/-sera), 
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rEMICE significantly reduced C3 deposition by about 90% (P=0.002, Figure 4-2C).  
EMICE’s ability to regulate the alternative pathway may help ECTV evade the innate and 
early adaptive immune response; however, after the induction of a strong humoral response, 
classical pathway activation may overwhelm EMICE’s regulatory capacity. 
Generation of  EMICE-deficient virus 
Loss of the complement regulatory protein affects local lesion size of cowpox and vaccinia 
virus [20,26]; however, these non-lethal infection models cannot address the hypothesis that 
loss of MOPICE produces the reduced mortality observed in the West African strains of 
monkeypox [25].  To attempt to address this, an EMICE-deficient ECTV (∆EMICE) was 
produced by deleting 600 bp from the middle of the EMICE gene in the wild-type Moscow 
strain of ECTV (WT).  The functional EMICE gene was restored in the ∆EMICE strain to 
produce the rescue strain (+EMICE).  EMICE-containing clones were selected by PCR, and 
EMICE production was confirmed by Western blotting (Figure 4-3).   
EMICE secreted early during infection, prior to the release of  virus 
To understand when and where EMICE might influence the infection, murine L929 cells 
were infected at an MOI of 1, washed, and then cultured in 1000 µl of media.  The EMICE 
produced was assessed in the supernatants and cells via Western blotting.  Given the low 
levels of EMICE observed at the earliest time points in prior experiments, the supernatants 
at initial time points were concentrated 10-fold (Figure 4-4A).  The blots of concentrated and 
neat supernatant show the EMICE contained in 10% or 1% of the total supernatant, 
respectively (Figure 4-4A & B).  To enable comparison, 10% of the total cells were also 
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analyzed (Figure 4-4C).  The quantity of EMICE produced was approximated using rEMICE 
as a standard (Figure 4-4D).  
EMICE was undetectable in the supernatant (Figure 4-4A) and cells (data not shown) 
at 0 h and in the samples from the ∆EMICE virus, which served as a control for potential 
cross-reaction of the antibody with other viral proteins.  In the concentrated supernatants at 
4 h, greater than 1 ng of EMICE was detected, indicating that the concentration was at least 
10 ng/ml.  In the next 2 h, the concentration of EMICE increased 10-fold to 100 ng/ml, as 
indicated by the 10 ng in the concentrated sample (Figure 4-4A) and about 1 ng in the 
unconcentrated supernatant (Figure 4-4B).  An additional 10-fold increase in EMICE 
concentration to 1000 ng/ml (1 µg/ml) occurred between 12–16 h since there was greater 
than 10 ng of EMICE in the unconcentrated supernatant at 16 h.  In contrast, minimal 
quantities of EMICE were detected in the cells at all time points (Figure 4-4C), which 
indicates that EMICE is predominately a secreted protein.   
The largest increase in infectious virus in the supernatant occurred between 16–18 h 
post-infection (Figure 4-4E).  The release of IMV from infected cells likely accounts for 
much of this increase, since the majority of the virus detected at 18 and 24 h post-infection 
was IMV (data not shown).  At 16 h, the EMICE level was 1000 ng/ml (Figure 4-4D), and 
most of rEMICE’s complement regulatory activity occurred in vitro at lower concentrations 
(Figure 4-1).  The large quantity of EMICE secreted from infected cells prior to the release 
of IMV could provide protection from complement-mediated destruction.  
102 
Soluble rEMICE protected ECTV IMV 
As described in chapter 3, mouse complement neutralizes the IMV form of ECTV 
effectively in vitro, even at serum concentrations as low as 10%.  Sera from mice genetically 
deficient in antibody or either classical or alternative pathway components had decreased 
activity.  Our prior data indicate that natural antibody initiates the classical complement 
cascade, and the subsequent engagement of the alternative pathway amplifies opsonization, 
the predominant process of neutralization in wild-type mice.   
To test EMICE’s ability to protect IMV, rEMICE or a control protein was mixed 
with wild-type mouse sera just prior to the addition of purified IMV.  The IL-18 binding 
protein of ECTV was used as a control because it was also produced in E. coli and is similar 
in size.  Sera (10%) neutralized 87% of the virus in the absence of recombinant protein.  The 
IL-18 binding protein did not affect neutralization, except slightly at the highest condition 
when the IL-18 binding protein and its buffer were 40% of the reaction volume (≤4% in all 
other conditions).  In contrast, rEMICE provides greater protection than the control with 
1000-fold less protein.  At the highest concentration, rEMICE reduced neutralization by 
85%.  However, protection of 50% of the virus occurred at a lower concentration, EC50 of 
280 ng/ml, as determined by non-linear regression.  This level is about 4-fold lower than the 
1 µg/ml concentration of EMICE observed in vitro (Figure 4-4D). 
∆EMICE and +EMICE ECTV were attenuated in wild-type mice and 
shared a similar change in plaque morphology 
The intranasal route of inoculation can produce a lethal infection in the normally resistant 
C57BL/6 mice.  This route was used to determine if a loss of EMICE expression would 
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reduce mortality in vivo.  The 100 pfu dose selected in the first set of experiments was 
intended to produce 50% morality in the wild-type mice.  Ideally, this dose would be 
sensitive to changes in virulence and would enable detection of increased susceptibility in the 
complement-deficient mice.   
This dose did produce significantly greater mortality in all three complement-
deficient strains compared to the wild-type mice (P<0.0001, Figure 2-5B).  However, a 
mortality difference between WT and ∆EMICE ECTV was not observed in wild-type mice 
at 100 pfu (Figure 4-6A).  Despite the similar mortality, the mice that received ∆EMICE 
ECTV appeared healthier 9 days post-infection, and had less weight loss compared to the 
mice that received the WT ECTV (data not shown).  Reproducible attenuation was 
demonstrated in wild-type mice at higher infectious doses (Figure 4-7).  At 100 pfu, 
∆EMICE ECTV was attenuated in the C3-/- (P=0.02, Figure 4-6B) and FB-/- (P=0.002, 
Figure 4-6C) mice.  In contrast, the two viruses produced equivalent mortality in the C4-/- 
mice (Figure 4-6D).  These data suggest that regulation of C4 may be EMICE’s primary role 
in vivo.  This ability to control classical pathway activation may be particularly advantageous as 
the virus confronts the host’s antiviral antibodies, either natural antibody in the first days of 
the infection or the initial adaptive response.   
At higher doses of WT ECTV that cause a uniformly lethal infection, significant 
attenuation was observed with the ∆EMICE ECTV (Figure 4-7).  Unfortunately, virulence 
was not consistently restored by replacing the EMICE gene (+EMICE ECTV).  During the 
course of these experiments, an increase in plaque size in the ∆EMICE and +EMICE ECTV 
compared to the WT ECTV was noticed when the cultures were accidently allowed to 
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overgrow for several days.  It therefore seems likely that the mutation responsible for the 
change in plaque size influenced the in vivo results and produced the attenuation observed in 
the ∆EMICE and +EMICE ECTV.  Alternatively, the attenuation observed in +EMICE 
ECTV could result from a second mutation acquired during the plaque purification process 
when generating the rescue strain.   
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Discussion 
At the amino acid (aa) sequence level, EMICE most closely resembles VCP (18 aa differ & 2 
aa deletion), then MOPICE (18 aa differ prior to the frame shift mutation), and finally 
SPICE (26 aa differ & 2 aa deletion) (Figure 1-5).  Over half (10 of 18) of the residues that 
are unique to EMICE occur in CCP-1, where the other PICEs are essentially identical.  This 
concentration of differences likely results from the co-evolution of ECTV with its host.  The 
changes presumably improve viral fitness by increasing EMICE’s ability to regulate mouse 
complement, similar to SPICE’s enhanced activity (vs. VCP) for human complement [19].  
Alternatively, natural ECTV infection is not subject to the selective pressures that have 
preserved CCP-1 in SPICE, VCP, and MOPICE.   
While several monoclonal antibodies to CCP-1 of VCP do not block functional 
activity [37], this domain is required for binding to C3b and C4b [28,34].  EMICE’s ability to 
bind C3b mirrored what was previously observed with MOPICE [24].  This similarity is 
particularly interesting given the structural variation between the two proteins: the 18 aa 
differences in addition to the truncation of CCP-4 in MOPICE.  Based on this line of 
reasoning, CCP-2,3 are the most important for ligand binding, which is consistent with 
electrostatic modeling [53] as well as a report that function blocking antibodies recognize 
either CCP-2 or CCP-3,4 [37].  Moreover, the differences in CCP-2 mediate SPICE’s 
enhanced activity compared to VCP [27,53].   
While PICEs bind both C3b and C4b, they bind C4b with higher affinity [24,34,54].  
Additionally, they have decay accelerating activity for the C4b containing convertases 
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generated by the classical and lectin pathways.  The pressures that have selected for this 
enhanced activity against C4 suggest that C4 has an important role in the immune response 
to a poxviral infection.  Since complement activation has antiviral effects that enhance host 
survival (Figures 2-1 & 2-5), the ability to inactivate C4b would be advantageous if the 
classical or lectin pathway initiates complement activation.  As indicated in chapter 3, natural 
antibody initiates the complement-mediated neutralization of IMV.   
Interestingly, EMICE protected CHO cells against complement activation by the 
alternative pathway using antibody as the activator.  Cofactor activity mediates this 
protection, since the other PICEs have limited or absent decay accelerating activity for the 
alternative pathway convertases [24,34,54].  EMICE’s regulation of the alternative pathway 
(and potentially the classical pathway when activated at a lower level by natural antibody) may 
help ECTV evade the innate and early adaptive immune response.   
A high-affinity rabbit IgG directed to CHO cells efficiently engages the classical 
pathway and overwhelmed the regulatory capacity of EMICE.  Prior reports using similar 
methods showed that SPICE decreased C3b deposition from the classical pathway by about 
50% [23]; however, this decrease would likely be insufficient to protect the cells from the 
detrimental results of complement activation (mimics the setting of abundant high-affinity 
antibody in an adaptive immune response).  The impact of the PICEs during infection likely 
occurs prior to the generation of a strong humoral response.   
EMICE’s ability to protect IMV from the complement-mediated neutralization 
initiated by natural antibody demonstrates its potential to regulate mouse complement in vivo 
and influence events early during infection.  Protection occurred at concentrations of 
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EMICE that were produced in vitro before most of the IMV was released.  The 
concentrations of EMICE reached in vivo may lower, but EMICE’s ability to dimerize and 
bind to cell surfaces may enhance its regulatory activity in the microenvironment of the 
infected cell.  While these experiments can only model what occurs in vivo, they demonstrate 
that infected cells produce large quantities of EMICE, and EMICE impedes neutralization of 
ECTV.   
ECTV infection produced multiple forms of EMICE.  The unpaired N-terminal 
cysteine of VCP economically mediates both dimer formation [24] and cell surface 
expression via its interaction with A56 [33].  Not only is this single residue responsible for 
tethering the complement inhibitor to the surface of infected cells, and possibly as well to the 
extracellular enveloped virus (EEV) form, but it also produces dimers with enhanced 
regulatory activity [24].  The multiple forms of the PICEs appear advantageous to the virus, 
as the only PICE that lacks a free N-terminal cysteine, MOPICE, has a free cysteine in the 
truncated CCP-4 that mediates dimerization [24].  The generation of ECTV mutants carrying 
EMICE lacking the N-terminal cysteine could address this question in vivo; however, 
differentiating between the effects of dimerization vs. A56 conjugation could be difficult.  
This potential interaction between EMICE and A56 and its contribution to the complement 
resistance of EEVs as well as virulence in vivo require future investigation.   
Generation of anti-PICE antibodies may help to clear the infection, and the passive 
administration of function-blocking antibodies could reduce virulence and aid recovery.  
These antibodies could enhance complement activity by disabling the inhibitor, while 
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simultaneously tagging infected cells that express PICEs on their surface for destruction by 
complement or other immune-mediated mechanisms.   
The increased mortality in the complement-deficient mice indicates how important 
this system is to antiviral defense, and it also underscores how delicate the balance between 
survival and mortality is in poxviral infections.  A lethal infection is not necessarily 
advantageous to the virus.  With a virus that primarily causes acute infections, evolution may 
favor viruses that replicate at high levels (to promote dissemination) without killing the host 
before transmission.  Since ECTV has coevolved with its murine host, the interactions 
between the two are likely more nuanced compared to other experimental models of poxviral 
infection.   
The difference between ∆EMICE and WT ECTV observed in the FB-/- mice 
supports an intriguing hypothesis about the delicate balance between the host’s defenses and 
a viral virulence factor.  While FB deficiency increased mortality from WT ECTV, natural 
antibody may still trigger the intact classical pathway in these mice and produce C4b and C3b 
deposition, albeit less efficiently than in a wild-type mouse.  Given the lack of the alternative 
pathway feedback loop in FB-/- mice, EMICE could better control complement activation in 
this setting, resulting in increased virulence.  In the absence of EMICE, unchecked 
complement activation by natural antibody could exert its antiviral activities, particularly the 
neutralization by the C4b and C3b opsonins, and thereby reduce the virulence of the 
infection.  The FB-/- mice infected with ∆EMICE ECTV have a mortality rate similar to 
wild-type mice infected with WT ECTV.  This similarity suggests that the combination of 
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these two deficiencies (FB-/- and ∆EMICE) maintains the equilibrium present in the wild-
type infection.   
While these data showing attenuation of ∆EMICE ECTV in FB-/- and C3-/- but not 
C4-/- mice are suggestive, a new ∆EMICE and rescue ECTV must be generated for a 
definitive analysis.  The similar mortality observed with the ∆EMICE and +EMICE viruses 
in the wild-type mice complicates interpretation of the in vivo data.  These results, combined 
with the change observed in plaque morphology of these two viruses, indicate that a second 
mutation was inadvertently selected during the generation of the ∆EMICE virus.  We cannot 
distinguish between this mutation being solely responsible for the attenuation observed or 
just masking the true effect of EMICE.   
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Figures 
Figure 4-1: rEMICE bound and regulated human complement activation fragments, 
C3b and C4b 
EMICE’s ability to interact with human C3b (A) or C4b (B) was measured using an ELISA 
format.   
(C)  The classical pathway C3 convertase was assembled on the surface of antibody-coated 
erythrocytes using purified human complement components.  The ability to dissociate the 
convertase was detected as decreased hemolysis when the cells were exposed the terminal 
complement components.   
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(D)  During C3b cofactor activity, Factor I (FI) inactivates C3b by cleaving the α or α´ chain 
into two fragments, α1 and α2.   
(E)  With C4b cofactor activity, factor I cleaves the α or α´ chain twice to release C4d from 
C4c.  C4c comprises the α chain fragments, α3 and α4, and the β and γ chains.   
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Figure 4-2: rEMICE bound cells and regulated the alternative pathway in mouse sera 
(A)  rEMICE bound CHO cells.  106 CHO cells were mixed with 20 µg of EMICE (heavy 
line), and rEMICE was detected with a polyclonal rabbit anti-VCP antibody.  Thin line 
represents cells not exposed to rEMICE.   
(B)  rEMICE significantly reduced C3 deposition by the alternative pathway.  CHO cells 
(gray) or CHO cells with rEMICE bound (black) were coated with anti-CHO antibody and 
exposed to sera from the indicated strains of mice.  C3 deposition was measured as mean 
fluorescence intensity (MFI) from two experiments performed in duplicate, and images from 
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one are shown (C).  In C4-/- sera, only the alternative pathway functions, and the decreased 
C3 deposition is indicated by the arrow.  Thin line represents cells not exposed to sera.   
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Figure 4-3: EMICE-deficient (∆EMICE) ECTV produced and then EMICE was 
restored (+EMICE) 
Two different crude lysates from the wild-type (WT) ECTV are shown.  ∆EMICE ECTV 
was generated using a construct with a 600 bp deletion in the middle of the EMICE gene.  
The wild-type genomic sequence was added back to ∆EMICE, and EMICE producing 
clones were selected by PCR and confirmed by Western blotting a crude stock of infected 
cells collected in supernatant.  The multiple forms of EMICE are labeled based on 
observations of VCP [33].  Some VCP is covalently bound to the viral membrane protein 
A56, and a similar interaction of EMICE with A56 may explain the largest band observed.  A 
smaller antigenically related protein of unknown significance is indicated by *.   
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Figure 4-4: Secretion of EMICE occurred early during infection 
(A-C)  The production of EMICE was followed over time in murine L929 cells infected at an 
MOI of 1.  After infection for 1 hour, the cells were rinsed to remove free virus and then 
cultured in 1000 µl of media.  The EMICE produced was assessed via Western blotting in 
(A) 10-fold concentrated supernatants (10% of total), (B) unconcentrated supernatants (1% 
of total), or (C) washed cells (10% of total).  The recombinant EMICE is labeled with the 
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amount of loaded (1 or 10 ng).  The numbers (0–24) indicate the time (h) when the samples 
were obtained.  ∆ indicates the ∆EMICE ECTV sample.   
(D)  The concentration of EMICE in the supernatant based on comparison to the 
recombinant EMICE. 
(E)  The supernatant was titrated on BS-C-1 cells at the time of collection.   
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Figure 4-5: Soluble EMICE protected IMV from complement-mediated 
neutralization 
Prior to the addition of purified IMV, mouse sera from naïve wild-type C57BL/6 mice were 
mixed with recombinant protein, EMICE or the ECTV IL-18 binding protein (IL-18 BP) as 
a control.  The lower dashed line shows the level of neutralization (87%) by the sera at a final 
concentration of 10%.  The data are normalized to heat-inactivated (HI) sera, and the 
EMICE line displays mean±SEM from two experiments performed in duplicate.  The gray 
curve was produced using non-linear regression.   
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Figure 4-6: The ∆EMICE mutation attenuated ECTV in C3-/- and FB-/- mice but not 
in C4-/- and wild-type mice 
The indicated strains of wild-type or complement-deficient male mice were inoculated 
intranasally with 100 pfu of wild-type (, solid) or ∆EMICE (, dashed) ECTV.  The 
numbers to the right of the curves indicate the number of animals in each group.  Survival 
curves were compiled from 3–7 separate experiments.   
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Figure 4-7: Attenuation observed in ∆EMICE remains in +EMICE ECTV 
Mice were inoculated intranasally with wild-type (), ∆EMICE (), or +EMICE () ECTV. 
(A)  Male mice received 500 pfu.   
(B)  Female mice received 250 pfu.   
The survival curves were constructed from four (A) or two (B) separate experiments.   
120 
References 
1. Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, et al. (2003) Poxviruses and 
immune evasion. Annu Rev Immunol 21: 377-423. 
2. Johnston JB, McFadden G (2003) Poxvirus immunomodulatory strategies: current 
perspectives. J Virol 77: 6093-6100. 
3. Turner PC, Moyer RW (2002) Poxvirus immune modulators: functional insights from 
animal models. Virus Res 88: 35-53. 
4. Johnston JB, McFadden G (2004) Technical knockout: understanding poxvirus 
pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol 6: 
695-705. 
5. Finlay BB, McFadden G (2006) Anti-immunology: evasion of the host immune system by 
bacterial and viral pathogens. Cell 124: 767-782. 
6. Alcami A (2003) Viral mimicry of cytokines, chemokines and their receptors. Nat Rev 
Immunol 3: 36-50. 
7. Lambris JD, Ricklin D, Geisbrecht BV (2008) Complement evasion by human pathogens. 
Nat Rev Micro 6: 132-142. 
8. Saifuddin M, Hedayati T, Atkinson JP, Holguin MH, Parker CJ, et al. (1997) Human 
immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored 
CD55 and CD59 and integral membrane CD46 at levels that protect from complement-
mediated destruction. J Gen Virol 78 ( Pt 8): 1907-1911. 
9. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, et al. (1995) Host cell-derived 
complement control proteins CD55 and CD59 are incorporated into the virions of two 
unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) 
and human cytomegalovirus (HCMV). J Immunol 155: 4376-4381. 
10. Vasantha S, Coelingh KL, Murphy BR, Dourmashkin RR, Hammer CH, et al. (1988) 
Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus 
neutralization. Virology 167: 433-441. 
11. Vanderplasschen A, Mathew E, Hollinshead M, Sim RB, Smith GL (1998) Extracellular 
enveloped vaccinia virus is resistant to complement because of incorporation of host 
complement control proteins into its envelope. Proc Natl Acad Sci U S A 95: 7544-7549. 
121 
12. Chung KM, Liszewski MK, Nybakken G, Davis AE, Townsend RR, et al. (2006) West 
Nile virus nonstructural protein NS1 inhibits complement activation by binding the 
regulatory protein factor H. Proc Natl Acad Sci U S A 103: 19111-19116. 
13. Stoiber H, Banki Z, Wilflingseder D, Dierich MP (2008) Complement-HIV interactions 
during all steps of viral pathogenesis. Vaccine 26: 3046-3054. 
14. Spiller OB, Morgan BP, Tufaro F, Devine DV (1996) Altered expression of host-encoded 
complement regulators on human cytomegalovirus-infected cells. Eur J Immunol 26: 
1532-1538. 
15. Fries LF, Friedman HM, Cohen GH, Eisenberg RJ, Hammer CH, et al. (1986) 
Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J 
Immunol 137: 1636-1641. 
16. Alcami A (2007) New insights into the subversion of the chemokine system by 
poxviruses. Eur J Immunol 37: 880-883. 
17. Favoreel HW, Van de Walle GR, Nauwynck HJ, Pensaert MB (2003) Virus complement 
evasion strategies. J Gen Virol 84: 1-15. 
18. Bernet J, Mullick J, Singh AK, Sahu A (2003) Viral mimicry of the complement system. J 
Biosci 28: 249-264. 
19. Rosengard AM, Liu Y, Nie Z, Jimenez R (2002) Variola virus immune evasion design: 
expression of a highly efficient inhibitor of human complement. Proc Natl Acad Sci U S 
A 99: 8808-8813. 
20. Isaacs SN, Kotwal GJ, Moss B (1992) Vaccinia virus complement-control protein 
prevents antibody-dependent complement-enhanced neutralization of infectivity and 
contributes to virulence. Proc Natl Acad Sci U S A 89: 628-632. 
21. Kotwal GJ, Isaacs SN, McKenzie R, Frank MM, Moss B (1990) Inhibition of the 
complement cascade by the major secretory protein of vaccinia virus. Science 250: 827-
830. 
22. Ciulla E, Emery A, Konz D, Krushkal J (2005) Evolutionary history of orthopoxvirus 
proteins similar to human complement regulators. Gene 355: 40-47. 
23. Liszewski MK, Bertram P, Leung MK, Hauhart R, Zhang L, et al. (2008) Smallpox 
inhibitor of complement enzymes (SPICE): regulation of complement activation on cells 
and mechanism of its cellular attachment. J Immunol 181: 4199-4207. 
24. Liszewski MK, Leung MK, Hauhart R, Buller RM, Bertram P, et al. (2006) Structure and 
regulatory profile of the monkeypox inhibitor of complement: comparison to homologs 
in vaccinia and variola and evidence for dimer formation. J Immunol 176: 3725-3734. 
122 
25. Chen N, Li G, Liszewski MK, Atkinson JP, Jahrling PB, et al. (2005) Virulence 
differences between monkeypox virus isolates from West Africa and the Congo basin. 
Virology 340: 46-63. 
26. Miller CG, Shchelkunov SN, Kotwal GJ (1997) The cowpox virus-encoded homolog of 
the vaccinia virus complement control protein is an inflammation modulatory protein. 
Virology 229: 126-133. 
27. Yadav VN, Pyaram K, Mullick J, Sahu A (2008) Identification of Hot Spots in the Variola 
Virus Complement Inhibitor (SPICE) for Human Complement Regulation. J Virol 82: 
3283-3294. 
28. Rosengard AM, Alonso LC, Korb LC, Baldwin WM, 3rd, Sanfilippo F, et al. (1999) 
Functional characterization of soluble and membrane-bound forms of vaccinia virus 
complement control protein (VCP). Mol Immunol 36: 685-697. 
29. Sahu A, Isaacs SN, Soulika AM, Lambris JD (1998) Interaction of vaccinia virus 
complement control protein with human complement proteins: factor I-mediated 
degradation of C3b to iC3b1 inactivates the alternative complement pathway. J Immunol 
160: 5596-5604. 
30. Murthy KH, Smith SA, Ganesh VK, Judge KW, Mullin N, et al. (2001) Crystal structure 
of a complement control protein that regulates both pathways of complement activation 
and binds heparan sulfate proteoglycans. Cell 104: 301-311. 
31. Smith SA, Mullin NP, Parkinson J, Shchelkunov SN, Totmenin AV, et al. (2000) 
Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus 
complement control proteins serve as putative heparin binding sites and contribute to 
inhibition of molecular interactions with human endothelial cells: a novel mechanism for 
evasion of host defense. J Virol 74: 5659-5666. 
32. Henderson CE, Bromek K, Mullin NP, Smith BO, Uhrin D, et al. (2001) Solution 
structure and dynamics of the central CCP module pair of a poxvirus complement 
control protein. J Mol Biol 307: 323-339. 
33. Girgis NM, Dehaven BC, Fan X, Viner KM, Shamim M, et al. (2008) Cell surface 
expression of the vaccinia virus complement control protein is mediated by interaction 
with the viral a56 protein and protects infected cells from complement attack. J Virol 82: 
4205-4214. 
34. Mullick J, Bernet J, Panse Y, Hallihosur S, Singh AK, et al. (2005) Identification of 
Complement Regulatory Domains in Vaccinia Virus Complement Control Protein. J 
Virol 79: 12382-12393. 
123 
35. Ganesh VK, Muthuvel SK, Smith SA, Kotwal GJ, Murthy KH (2005) Structural Basis for 
Antagonism by Suramin of Heparin Binding to Vaccinia Complement Protein(,). 
Biochemistry 44: 10757-10765. 
36. Ghebremariam YT, Odunuga OO, Janse K, Kotwal GJ (2005) Humanized Recombinant 
Vaccinia Virus Complement Control Protein (hrVCP) with Three Amino Acid Changes, 
H98Y, E102K, and E120K Creating an Additional Putative Heparin Binding Site, Is 100-
fold More Active Than rVCP in Blocking Both Classical and Alternative Complement 
Pathways. Ann N Y Acad Sci 1056: 113-122. 
37. Isaacs SN, Argyropoulos E, Sfyroera G, Mohammad S, Lambris JD (2003) Restoration of 
complement-enhanced neutralization of vaccinia virus virions by novel monoclonal 
antibodies raised against the vaccinia virus complement control protein. J Virol 77: 8256-
8262. 
38. Smith SA, Sreenivasan R, Krishnasamy G, Judge KW, Murthy KH, et al. (2003) Mapping 
of regions within the vaccinia virus complement control protein involved in dose-
dependent binding to key complement components and heparin using surface plasmon 
resonance. Biochim Biophys Acta 1650: 30-39. 
39. Liszewski MK, Leung M, Cui W, Subramanian VB, Parkinson J, et al. (2000) Dissecting 
sites important for complement regulatory activity in membrane cofactor protein (MCP; 
CD46). J Biol Chem 275: 37692-37701. 
40. Liszewski MK, Leung MK, Atkinson JP (1998) Membrane cofactor protein: importance 
of N- and O-glycosylation for complement regulatory function. J Immunol 161: 3711-
3718. 
41. Barilla-LaBarca ML, Liszewski MK, Lambris JD, Hourcade D, Atkinson JP (2002) Role 
of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J 
Immunol 168: 6298-6304. 
42. Falkner FG, Moss B (1990) Transient dominant selection of recombinant vaccinia 
viruses. J Virol 64: 3108-3111. 
43. Earl PL, Moss B, Wyatt LS, Carroll MW (2001) Generation of recombinant vaccinia 
viruses. Curr Protoc Mol Biol Chapter 16: Unit16 17. 
44. Chen W, Drillien R, Spehner D, Buller RM (1992) Restricted replication of ectromelia 
virus in cell culture correlates with mutations in virus-encoded host range gene. Virology 
187: 433-442. 
45. Circolo A, Garnier G, Fukuda W, Wang X, Hidvegi T, et al. (1999) Genetic disruption of 
the murine complement C3 promoter region generates deficient mice with extrahepatic 
expression of C3 mRNA. Immunopharmacology 42: 135-149. 
124 
46. Suresh M, Molina H, Salvato MS, Mastellos D, Lambris JD, et al. (2003) Complement 
component 3 is required for optimal expansion of CD8 T cells during a systemic viral 
infection. J Immunol 170: 788-794. 
47. Matsumoto M, Fukuda W, Circolo A, Goellner J, Strauss-Schoenberger J, et al. (1997) 
Abrogation of the alternative complement pathway by targeted deletion of murine factor 
B. Proc Natl Acad Sci U S A 94: 8720-8725. 
48. Wu X, Spitzer D, Mao D, Peng SL, Molina H, et al. (2008) Membrane protein Crry 
maintains homeostasis of the complement system. J Immunol 181: 2732-2740. 
49. Fischer M, Ma M, Goerg S, Zhou X, Xia J, et al. (1996) Regulation of the B cell response 
to T-dependent antigens by classical pathway complement. J Immunol 157: 549-556. 
50. Kitamura D, Roes J, Kuhn R, Rajewsky K (1991) A B cell-deficient mouse by targeted 
disruption of the membrane exon of the immunoglobulin [mu] chain gene. Nature 350: 
423-426. 
51. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, et al. (1998) 
Homozygous C1q deficiency causes glomerulonephritis associated with multiple 
apoptotic bodies. Nat Genet 19: 56-59. 
52. Xu Y, Ma M, Ippolito GC, Schroeder HW, Jr., Carroll MC, et al. (2001) Complement 
activation in factor D-deficient mice. Proc Natl Acad Sci U S A 98: 14577-14582. 
53. Sfyroera G, Katragadda M, Morikis D, Isaacs SN, Lambris JD (2005) Electrostatic 
modeling predicts the activities of orthopoxvirus complement control proteins. J 
Immunol 174: 2143-2151. 
54. McKenzie R, Kotwal GJ, Moss B, Hammer CH, Frank MM (1992) Regulation of 
complement activity by vaccinia virus complement-control protein. J Infect Dis 166: 
1245-1250. 
 
 
125 
Chapter 5 
Conclusions and Future Directions 
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Conclusions 
The mousepox model offered an uncommon opportunity to characterize the role of the 
complement system in the host-poxvirus relationship using a pathogen and a host that have 
co-evolved.  The major goal of this thesis was to test the hypothesis that the complement 
system plays a role in defense against ectromelia virus (ECTV) infection and that ECTV 
counters the effects of complement by producing EMICE (EctroMelia Inhibitor of 
Complement Enzymes).  Exploring aspects of both the host and the virus provided a better 
understanding of the delicate balance that occurs in this relationship.   
The in vivo studies employing C3-/-, C4-/-, and FB-/- mice establish that multiple 
complement activation pathways are required to survive ECTV infection initiated by three 
routes of inoculation.  In the C3-deficient mice, ECTV disseminated from the inoculation 
site earlier and produced higher viral titers in the target organs.  Additionally, the minority of 
C3-/- mice that survived to day 10 post-infection had an active infection in these organs, while 
most wild-type mice had cleared the infection.  The early dissemination observed in the C3-/- 
mice prompted an investigation into the ability of the murine complement system to directly 
neutralize ECTV.   
The in vitro experiments employed sera from the same strains used to characterize the 
effect of complement deficiency in vivo, and the neutralizing capacity in vitro paralleled the in 
vivo mortality observed.  Naïve mouse sera neutralized the intracellular mature virus (IMV) of 
ECTV in vitro, and sera lacking either classical or alternative pathway components had 
decreased activity.  Several lines of evidence indicate that natural antibody initiated the 
classical complement cascade in the wild-type mouse.  Substantial neutralization occurred in 
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sera without lytic activity, which points to opsonization as the predominant mechanism of 
neutralization.  Based on these results, we propose that natural antibody binds viral antigen 
to activate the classical pathway, followed by engagement of the alternative pathway’s 
feedback loop to further opsonize the virus.  The delayed mortality observed in the µMT 
mice treated with naïve sera underscores the importance of natural antibodies to protection.  
The ability of natural antibody to neutralize ECTV in turn depends upon its ability to activate 
the complement system.  This likely accounts for why the virus encodes a complement 
regulatory protein.   
EMICE was obtained by using recombinant protein technology as well as through 
infection of a murine cell line.  Recombinant, and presumably murine, EMICE had both 
cofactor and decay accelerating activity for human complement, and it protected cells from 
the activation of mouse complement via the alternative pathway.  It also prevented 
complement-mediated neutralization of the IMV at concentrations produced by the infected 
cell in vitro.   
Given that poxviruses must face both natural antibody and the complement system 
to establish an infection, a virus lacking its regulator would be at a greater risk of being 
neutralized by complement activity.  Our results support the supposition that the loss of this 
regulator contributes to the reduced virulence of some strains of monkeypox virus [1].  From 
the host’s perspective, the complement system is critical to the innate immune response to 
poxviruses.  It reduces viral spread and decreases tissue titers and, therefore, cellular damage 
in target organs.  
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Future Directions 
This characterization of the role of the complement system during ECTV infection has 
raised multiple questions that are now under investigation.  The availability of genetically 
modified mouse strains makes the ectromelia model a powerful one for addressing these 
issues.   
Complement effector mechanisms in vivo   
The early mortality of the C3-/-, C4-/-, and FB-/- mice demonstrates an essential role for the 
classical and alternative pathways in the initial stages of a poxvirus infection.  Despite 
equivalent mortality levels, further analysis will define distinct functions for each complement 
pathway in vivo, as such differences exist in the immune response to other viruses [2].  
Undoubtedly, complement deposition triggers other effector functions, such as recruiting 
inflammatory cells, promoting phagocytosis, and priming the adaptive immune response.  
The precise contribution of each of these to protection in vivo remains unexplored.  
The similarity between the in vivo mortality and in vitro serum neutralization 
experiments suggests that complement neutralizes ECTV and, thereby, limits its spread.  
Determining if, when, where, and how this neutralization occurs would provide insight into 
the roles for each of the pathways.  The ability of C3 to reduce or delay the spread of ECTV 
from the inoculation site to the spleen on day two post-infection suggests three sites where 
this neutralization likely occurs: the inoculation site/primary lesion, the draining lymph node 
(memory CD8+ T cells control infection here [3]), and the bloodstream.   
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An initial investigation would examine the amount of infectious virus at the 
inoculation site and in the draining lymph node immediately, a few hours, and a day after 
infection of wild-type and complement-deficient mice.  Should the viral titer at the 
inoculation site be significantly reduced in the wild-type mice, as we predict, it would be 
interesting to assess if inclusion of recombinant EMICE would protect the inoculated IMV 
from neutralization.  Additionally, if complement-mediated neutralization at the inoculation 
site is an important mechanism of C57BL/6 resistance, then reducing complement activation 
through inclusion of EMICE may enhance the virulence of the infection.  Similar increases in 
virulence could result from inoculation with extracellular enveloped virus (EEV), as this form 
resists complement activation through incorporation of complement regulators in its 
outermost viral membrane.  Thus, these approaches could provide a method for initiating 
virulent infection in other poxvirus models that typically use IMV, such as the non-human 
primate modes for monkeypox or variola virus.   
Our in vitro data demonstrate the susceptibility of the IMV form to complement-
mediated neutralization, and this strongly suggests that ECTV disseminates through the 
bloodstream either inside infected cells or in the EEV form.  Determining which of these is 
the case should provide insight into viral pathogenesis.  If EEVs are primarily responsible for 
the viremia, this would explain the ability of anti-EEV antibodies, either passively transferred 
[4] or generated to recombinant protein [5-7], to protect against a lethal infection.   
Alternatively, if infected cells mediate systemic dissemination, then this raises the 
question of what types of cells are responsible, when and where they acquired the infection, 
and what is their final destination.  A logical extension of our work would be to examine the 
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participation of complement receptors in this process.  A consideration is that a limited 
amount of complement deposition could aid viral entry into cells bearing complement 
receptors, like B cells, dendritic cells, and macrophages [8].  The fate of IMV bearing sub-
neutralizing levels of complement could be followed when combined with phagocytic cells 
that possess or lack complement receptors.  We hypothesize that phagocytosis would result 
in destruction and decreased viral titers; however, its potential to enhance infection under 
certain conditions cannot be ruled out.  Infection studies in mice deficient in complement 
receptors could address the importance of these proteins in vivo.  Of particular interest are 
CR1/2, due to its expression on cell types that are infected in vivo [9], and CRIg, for its 
potential to mediate the hepatic clearance of ECTV introduced intravenously [10].   
Role of  antibody during ECTV infection 
The ability of heat-inactivated wild-type sera to restore the neutralizing activity of µMT sera 
in vitro indicates that natural antibody is important in the neutralization process.  The acute 
mortality observed in the µMT mice combined with the ability of the passive transfer of 
normal sera to lengthen survival suggests that natural antibody helps control the acute 
infection in vivo.  However, the eventual death of these animals demonstrates that the other 
activities of B cells are also required for survival of ECTV infection.  Mice deficient in 
secreted IgM, yet retaining B cells and some ability to generate an antiviral humoral response, 
would help distinguish between the role of natural antibody vs. these other activities [11,12].   
Since human sera also neutralize IMV, characterization of the natural antibody 
population present in C57BL/6 mice may provide insight into human poxviral infection.  An 
initial step would be to determine the isotype of the natural antibody population that 
131 
recognizes poxviruses.  Natural antibody presumably reacts with an epitope found on the 
IMV particle based on the neutralization observed.  Natural antibody may also bind EEV 
antigens given that a polyreactive repertoire mediates the antibacterial activity of natural 
antibody when combined with complement [13].  The regulatory proteins present in the 
membrane of the EEV contribute to its resistance to complement [14]; however, lower levels 
of natural antibody to the EEV compared to the IMV may also reduce complement 
activation.  Determining the viral antigens recognized would contribute to our understanding 
of the role of the EEV form in vivo.   
A similar analysis of the earliest humoral response would provide additional 
perspective on this topic.  Examining when neutralizing antibodies to IMV and EEV 
develop would provide perspective on what antigens have stimulated the immune response.  
The addition of complement to the EEV neutralization assay may enhance detection.  
Additionally, the ability of complement to hasten the development of the EEV neutralizing 
response should also be assessed.  In preliminary experiments, C3-/- mice have lower levels of 
anti-ECTV IgG on day 10 with a significant difference on day 16.   
Characterization of  EMICE in vivo  
The large quantities of EMICE produced by infected cells along with its ability to protect 
ECTV IMV in the fluid phase in vitro prompt, as a logical extension of our work, further 
investigation into EMICE’s ability to bind virus particles, protect infected cells, and modulate 
the local environment.  Of specific interest are the EMICE levels systemically (in the 
bloodstream) and at the primary lesion, as well as EMICE’s effect on complement activation 
at the inoculation site.  Complement activation and release of anaphylatoxins is important for 
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recruiting inflammatory cells to the site of infection [15].  If EMICE reduced complement 
activation at the inoculation site, then detectible changes may occur in the inflammatory 
response, either in quantity or in character. 
EMICE may also protect infected cells, which could be assessed using infected 
mouse cells and a protocol similar to the CHO cell assay.  Hypothetically, host cells may 
decrease production of their regulators during infection to increase their susceptibility to 
complement, and EMICE may be expressed on the cells’ surfaces to compensate.  Flow 
cytometry could assess changes in the levels of the host regulators and EMICE after 
infection.  If the regulator levels decrease, then the ability of recombinant protein to bind to 
or protect cells infected with ∆EMICE ECTV would mimic the ability of secreted EMICE 
to protect surrounding infected cells during this period.  EMICE has conserved the heparin 
binding sites in CCP-1, despite the numerous other changes in this domain, which may 
enhance its protective abilities.   
Similar to VCP [16], cell surface expression of EMICE may result from an 
interaction with the viral protein A56, which is suggested by the high molecular weight band 
present on Western blots of infected cell cultures.  Such an interaction may also target 
EMICE to the EEV.  Proteomic analysis of IMV and EEV from vaccinia and monkeypox 
viruses produced in HeLa cells suggests that these viruses use different mechanisms to 
protect EEV from complement [17].  The IMV forms of both viruses had neither the viral 
nor the host regulators.  Vaccinia EEV contained VCP and high levels of A56, while 
monkeypox EEV lacked MOPICE and had only minimal A56.  Instead, monkeypox EEV 
had high levels of the host regulators (DAF and CD59), which were absent in the vaccinia 
133 
EEV.  Given that VCP forms a covalent linkage to A56 on the surface of infected cells, it 
seems likely that this mechanism explains VCP’s presence in the EEV [16].  EMICE’s 
influence on the complement resistance of the EEV remains to be determined.   
Along the same lines, the influence of the dimerized form of EMICE or the other 
PICEs in vivo is unknown.  Unfortunately, a single cysteine mediates dimer formation and 
A56 conjugation, which complicates assessment of the significance of the various forms in 
vivo.  While our in vivo data are suggestive, to definitely examine the role of EMICE in vivo, a 
new ∆EMICE ECTV mutant must be produced.  Versions of EMICE lacking the N-
terminal cysteine or the heparin binding sites, in addition to the wild-type protein, could be 
reintroduced to the ∆EMICE mutant.  The collection of resulting viruses could begin to 
address the role of the A56 conjugation/dimer formation and heparin binding in vivo.  If 
∆EMICE ECTV is attenuated, then genetic complementation should occur in a C3-/- × C4-/- 
mouse, since these are the two complement proteins that EMICE targets.  Further analysis 
of this attenuation could reveal when ∆EMICE ECTV deviates from a normal infection.  
How EMICE deficiency changes the pathogenesis and virulence of ECTV has implications 
for targeting the PICEs to therapeutically modulate the virulence of human poxviral 
infections. 
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